Systems and methods for virtual index-matching of diffusive media

ABSTRACT

The invention relates to systems and methods for tomographic imaging of a subject comprising diffuse media by converting measurements of electromagnetic radiation, e.g., fluorescent light, obtained in free space exterior to the subject into data that would be measured if the subject were surrounded by an infinite and homogeneous diffusive medium, e.g., a medium with optical properties equal to the average optical properties of the subject. After applying a transformation to convert measurements to virtually-matched values, propagation of light is simulated from the index-matched surface to a set of virtual detectors exterior to the subject and arranged in a geometrically advantageous fashion, for example, in a planar array, thereby facilitating the use of fast reconstruction techniques.

RELATED APPLICATION

This application claims priority to and the benefit of, and incorporatesherein by reference in its entirety, U.S. Provisional Patent ApplicationNo. 61/244,674, which was filed on Sep. 22, 2009.

FIELD OF THE INVENTION

The invention relates generally to in vivo imaging systems and methods.More particularly, in certain embodiments, the invention relates to atomographic imaging system employing a virtual index matching technique.

BACKGROUND OF THE INVENTION

Tomography is based on utilizing data sets to obtain images or infer theoptical properties of the medium under study. Many different numericaland analytical approaches have been developed for modeling photonpropagation and effectively provide the solutions necessary fortomographic inversion of the data sets collected. This has grown into anactive field (see, e.g., Ntziachristos, Ripoll et al. (2005) “Lookingand listening to light: the evolution of whole-body photonic imaging.”Nat. Biotechnol. 23 (3): 313-320 and Arridge, Dehghani et al. (2000)“The finite element model for the propagation of light in scatteringmedia: a direct method for domains with nonscattering regions.” Med.Phys. 27(1):252-264 for reviews). For the most general case of imaging asubject with arbitrary geometries, numerical techniques are mostpertinent. In all these numerical methods, the objective is to determinethe distribution of luminescent or fluorescent sources inside aheterogeneous or homogeneous medium from a relatively small number ofsurface measurements (in the order of 10²-10³). With improvements indetector technology and computational platforms, higher numbers ofmeasurements have become possible, which has led to new numericalmethods that can deal with such large data sets. These techniques havebeen developed so as to reduce the memory and computing time needed tosolve for such large systems of equations (see, e.g., Ripoll,Ntziachristos et al. (2001) “The Kirchhoff Approximation for diffusivewaves.” Phys. Rev. E. 64: 051917:1-8; Ripoll, Nieto-Vesperinas et al.(2002) “Fast analytical approximation for arbitrary geometries indiffuse optical tomography.” Opt. Let. 27(7): 527-529; and Markel andSchotland (2004) “Symmetries, inversion formulas, and imagereconstruction for optical tomography.” Phys. Rev. E Stat Nonlin SoftMatter Phys. 70(5 Pt 2): 056616). At present, however, a point has beenreached where a compromise is needed when dealing with arbitrarygeometries: either accurate methods are used by reducing considerablythe size of the data sets (see, e.g., Hielscher, Alcouffe et al. (1998)“Comparison of finite-difference transport and diffusion calculationsfor photon migration in homogenous and heterogeneous tissues.” Phys.Med. Biol. 43: 1285-1302 and Arridge, Dehghani et al. (2000) “The finiteelement model for the propagation of light in scattering media: a directmethod for domains with nonscattering regions.” Med. Phys.27(1):252-264), or approximate methods are employed to speed upcalculations at the expense of the accuracy of the result (see, e.g.,Ripoll, Ntziachristos et al. (2001) “The Kirchhoff Approximation fordiffusive waves.” Phys. Rev. E. 64: 051917:1-8).

SUMMARY OF THE INVENTION

The invention relates to systems and methods for tomographic imaging ofa diffuse subject by converting measurements of electromagneticradiation (e.g., fluorescent light) obtained in free space, exterior tothe subject, into data that would be measured if the subject weresurrounded by an infinite and homogeneous diffusive medium, e.g., amedium with optical properties equal to the average optical propertiesof the subject. After applying a transformation to convert measurementsto virtually-matched values, propagation of light is simulated from theindex-matched surface to a set of virtual detectors exterior to thesubject and arranged in a geometrically advantageous fashion, forexample, in a planar array, thereby facilitating the use of fastreconstruction techniques. In particular embodiments, the inventionfeatures methods of fluorescence molecular tomographic (FMT)reconstruction in vivo of signals, reporters and/or agents (i.e.,contrast agents or probes) in a diffusive medium (e.g., a mammaliansubject). The method preserves the three-dimensional fluorophoredistribution and quantitative nature of the FMT approach whilesubstantially accelerating its computation speed and simplifying theunderlying equations.

In preferred embodiments, systems and methods of the invention transformfluorescence measurements to those that would be obtained if thesurrounding non-diffusive medium were filled with a diffusive mediumwith the same optical properties as those of the object. This situationwould then correspond to the case where the original diffusive volume isinfinite and homogeneous. This technique has two important consequences.First, it allows the use of infinite homogeneous functions (e.g.,Green's functions) to generate analytical forward solutions for theinverse problem, thereby avoiding the use of complex numerical methodswhich solve for arbitrary geometries. This has a direct impact insignificantly accelerating the computation for tomographic images.Second, this technique allows for propagating the data to virtualdetectors located anywhere outside the volume, thereby facilitating theconformation of detector areas to any general shape, in particular to aplanar array of detectors. This enables the use of exact inversionmethods such as those proposed in Markel and Schotland (2001) “Inversescattering for the diffusion equation with general boundary conditions.”Phys. Rev. E. 64(3 Pt 2): 035601 and Markel and Schotland (2004)“Symmetries, inversion formulas, and image reconstruction for opticaltomography.” Phys. Rev. E Stat Nonlin Soft Matter Phys. 70(5 Pt 2):056616) and the application of fast reconstruction methods such as theHybrid approach (see, e.g., U.S. patent application Ser. No. 12/870,454,“Systems and Methods for Tomographic Imaging in Diffuse Media using aHybrid Inversion Technique,” by Ripoll Lorenzo et al.).

Furthermore, once outside the diffusive volume, data can beback-propagated inside the diffusive volume, a transformation which isnot possible in the presence of arbitrary interfaces. The technique canbe used, for example, to recover the spatial distribution andconcentration of fluorescent signatures in an arbitrary geometry byvirtually index-matching the surface measurements and using thenormalized Born approximation (see, e.g., U.S. Pat. Nos. 6,615,063 and7,383,076, both entitled “Fluorescence-Mediated Molecular Tomography,”and International Patent Application No. PCT/US2008/65648, entitled,“Imaging Systems Featuring Waveguiding Compensation”).

Embodiments of the present invention can be used in combination withvarious solutions of the diffuse problem, including numerical and/oranalytical solutions of the transport equation, or its derivations andapproximations such as the Boltzmann Equation or the Diffusion Equation.As such, certain embodiments of this invention can also be used forresolving absorption, scattering or fluorescence contrast and incombination with contrast agents and molecular probes. The indexmatching techniques described herein are applicable where the diffusionregime dominates. Hence, the techniques are applicable not only to lightdiffusion but also to electron and neutron diffusion and any otherdiffusive process such as electromagnetic propagation of all wavelengthsin highly scattering media such as microwave scattering from randomscatterers, or sound diffusion in highly scattering media.

An early technique for boundary removal in diffuse media was describedin Ripoll et al. (2006) “From finite to infinite volumes: removal ofboundaries in diffuse wave imaging.” Phys. Rev. Lett. 96: 173903; theInternational (PCT) Patent Application Publication No. WO2007/072085,entitled, “Removal of Boundaries in Diffuse Media,” and Greek Patent No.1005346 (Application No. 20050100621), each of which are incorporatedherein by reference. This technique is not suitable for use withfluorescence molecular tomography (FMT) or any other technique wherequantitation is pursued. Where quantitation is pursued, as in the FMTapproach, fluorescence must be considered in the context of theexcitation source (referred to as the primary source), in which casefluorescence becomes a primary source-dependent secondary source. Thismeans that the boundary removal equations used in the early techniqueare not sufficient to recover quantitatively the concentration offluorophores, and would be adversely affected by tissue heterogeneity ingeneral. In order to overcome these significant drawbacks, the virtualmatching techniques of the present invention include transformation anduse of the excitation source measurements to normalize the fluorescencemeasurements. This enables quantitative fluorescence imaging inheterogeneous media.

Preferred embodiments of the invention utilize a transformation thatconverts fluorescent data obtained from a diffusive object surrounded byfree space (air, for example) into data that would be obtained if thesame object were surrounded by an optically matching diffusive medium.This is done by applying the surface integral equations to anarbitrarily-shaped medium surrounded by free space and adding a termthat would be present if the subject were embedded in a diffusive mediumwith the same optical properties. This “virtual index-matching”technique accounts for a refractive index mismatch between the mediawithin the subject and the media (e.g., air) outside the subject. Oncethe data has been virtually index-matched it can be propagated withinthe virtual matched medium to a set of virtual detectors locatedarbitrarily and conforming to arbitrary geometries, including but notlimited to, a planar array.

For example, in preferred embodiments, the detector data is transformedto its virtually-matched equivalent. This enables the use of infinitehomogeneous functions for the weight matrix. This additionally enablesfull body imaging and the imaging of larger anatomies, since thecomplexity of reconstructing arbitrary shapes is now drasticallyreduced.

The invention provides systems and methods for transforming datasets totheir virtually-matched equivalents for the purpose of reconstructingthree-dimensional quantitative distributions of signal. These methodsyield a faster and still accurate depiction of the localization anddistribution of the signal in the object/subject, includingquantification and distribution of signals, reporters and/or agents(i.e., contrast agents or probes) in such objects/subjects than can beachieved by conventional tomographic reconstruction techniques.

In accordance with certain embodiments of the present invention, fasttomographic reconstruction methods and algorithms can be applied byconforming the virtually-matched detectors to a planar array asdescribed herein. The methods and algorithms have been fullyparameterized to accommodate different imaging settings optimized for avariety of target objects/subjects and regions and a variety ofdifferent agents or probes. In particular, it is an object of theinvention to provide such algorithms and a calibration and imagecorrection analysis methods for use in biological research, as well asin preclinical and/or clinical settings. In particular, the presentinvention provides corrected and calibrated imaging algorithms that canoptionally be used with one or more imaging agent or probes for in vivomolecular imaging.

In one aspect, the invention provides for a fluorescent moleculartomography system comprising: an excitation source; an optical imagingapparatus configured to direct light from the excitation light sourceinto a subject at a plurality of locations; a detector configured todetect at multiple locations light emanating from a region within thesubject; and a processor configured to process data corresponding to thedetected light emanating from the region of the subject to produce atomographic representation of the region of the subject, wherein theprocessor is configured to execute instructions to: (a) establish aforward model of excitation light propagation from the region to thedetector using the data corresponding to the detected fluorescent light,wherein one or more virtual-matching transformation(s) is/are applied tothe data corresponding to the detected fluorescent light to account fora refractive index discontinuity at the surface of the subject, and theforward model is established as a weight matrix of elements using one ormore infinite homogeneous functions such that light propagation ismodeled as if there is no discontinuity in refractive index at thesurface of the subject; and (b) invert the weight matrix to obtain thetomographic representation of the region of the subject. In certainembodiments, in the forward model, the excitation light source isrepresented in real space and the detected fluorescent light isrepresented in frequency space (e.g., thereby facilitating hybridreconstruction), and the tomographic representation of the region of thesubject is a representation in real space. Furthermore, in the forwardmodel, virtual detectors can be established that conform to an imposedgeometry different from the arrangement of the actual detectors (e.g.,and the forward model simulates light propagation from the region of thesubject). For example, the imposed geometry can be a planar array.

In certain embodiments, the detector is further configured to detect atmultiple locations excitation light emanating from the subject, andwherein the processor is configured to execute instructions to establishthe forward model using the data corresponding to the detectedexcitation light and the detected fluorescent light. Furthermore, incertain embodiments, in the forward model, one or more virtual-matchingtransformations is/are applied to the data corresponding to the detectedexcitation light. In addition, in certain embodiments, in the forwardmodel, the excitation light source is represented in real space, thedetected excitation light is represented in frequency space, thedetected fluorescent light is represented in frequency space, and thetomographic representation of the region of the subject is arepresentation in real space.

In certain embodiments, an experimental measurement of surface fluxdistribution is used in the forward model.

In certain embodiments, the detected fluorescent light is emitted from aprobe within the region of the subject, and the forward model in (a)models excitation light propagation from the excitation light source tothe probe and emitted fluorescent light propagation from the probe tothe detector. In addition, in the forward model, a Born approximation isused to express an intensity of the detected fluorescent light emittedfrom the probe having spatially-varying concentration within the region.In other embodiments, the intensity of the detected fluorescent light isnormalized using an intensity of the spatially-corresponding detectedexcitation light. In preferred embodiments, this facilitates the displayof a quantitative concentration of a fluorophore within the subject bythe tomographic representation of the region. The detected excitationlight is preferably detected after passing through at least a portion ofthe subject, and the subject is preferably transilluminated withexcitation light. In addition, the forward model is preferablyestablished as a weight matrix of normalized elements. Furthermore, theforward model in (a) represents the detected excitation light and thedetected fluorescent light in corresponding virtually-matchedexpressions.

In certain embodiments, the excitation light source or the opticalimaging apparatus comprises a scanner configured to direct light intothe subject at a plurality of locations, thereby defining a plurality ofsource locations. In certain embodiments, the plurality of sourcelocations are non-uniformly spaced. In certain embodiments, the detectorcomprises an array of detector locations, and the forward model isestablished using data obtained from the array of detector locations. Incertain embodiments, there are substantially more detector locationsthan source locations.

In certain embodiments, the optical imaging apparatus comprises achamber. In other embodiments, the chamber is an animal chamber.

In certain embodiments, the subject is a human.

In certain embodiments, the excitation light is near-infrared light. Inaddition, the excitation light has a wavelength within a range fromabout 500 nanometers to about 1000 nanometers. In other embodiments, theexcitation light has a wavelength within a range from about 635nanometers to about 850 nanometers.

In certain embodiments, the excitation light is continuous wave (CW)light. The excitation light comprises at least one member selected fromthe group consisting of continuous wave light, time-resolved light, andintensity modulated light.

In certain embodiments, the forward model models excitation lightpropagation from the excitation light source to the region of thesubject and fluorescent light propagation from the region to thedetector, where there is free space between the surface of the subjectand the detector.

In another aspect, the present invention provides methods for imagingusing the virtual-matching transformation on the measured data in orderto image the distribution of a fluorescent probe within a region of asubject, the method comprising the steps: (a) administering to thesubject a probe comprising a visible or near-infrared fluorophore; (b)directing visible or near-infrared excitation light into the subject atmultiple locations to transilluminate through or reflect from at least aportion of the region of the subject containing the fluorescent probe;(c) detecting excitation light transmitted through or reflected from theregion of the subject; (d) detecting fluorescent light emitted from theprobe within the subject; and (e) processing data corresponding to thedetected fluorescent light, and, the detected excitation light, toprovide a tomographic representation of the region of the subject,wherein the processing step comprises (i) establishing a forward modelof excitation light propagation from an excitation light source to theprobe within the subject and of emission light propagation from theprobe to a detector using the data corresponding to the detectedfluorescent light and, the detected excitation light, wherein: one ormore virtual-matching transformation(s) is/are applied to the datacorresponding to the detected fluorescent light and the datacorresponding to the detected excitation light account for a refractiveindex discontinuity (e.g., mismatch) at the surface of the subject; anintensity of the detected fluorescent light is normalized using anintensity of spatially-corresponding detected excitation light; and theforward model is established as a weight matrix of normalized elementsusing one or more infinite homogeneous functions such that lightpropagation is modeled as if there is no discontinuity in refractiveindex at the surface of the subject; and (ii) inverting the weightmatrix to obtain the tomographic representation of the region of thesubject. In certain embodiments, in the forward model, the excitationlight source is represented in real space and the detected fluorescentlight is represented in frequency space (e.g., thereby facilitatinghybrid reconstruction), and wherein the tomographic representation ofthe region of the subject is a representation in real space.Furthermore, in the forward model, virtual detectors can beadvantageously established to conform to an imposed geometry differentfrom the arrangement of the actual detectors (e.g., and the forwardmodel simulates light propagation from the region of the subject to thevirtual detectors). For example, the imposed geometry can be a planararray. In certain embodiments, the invention is a method of obtaining anexperimental measurement of surface flux distribution for the surface ofthe subject, wherein the experimental measurement of surface fluxdistribution is used in the forward model. Furthermore, in the forwardmodel, a Born approximation can be used to express an intensity of thedetected fluorescent light emitted from the probe havingspatially-varying concentration within the subject.

In certain embodiments, the forward model in step (e) represents thedetected fluorescent light and the detected excitation light incorresponding virtually-matched expressions.

In another aspect, the present invention provides methods for imagingusing a virtual-matching transformation technique to image thedistribution of a fluorescence within a region of a subject, includingbut not limited to endogenous fluorescence, bioluminescence orfluorescent proteins, the method comprising: (a) directing excitationlight into the subject at multiple locations to transilluminate throughor reflect from at least a portion of the region of the subjectcontaining the fluorescence; (b) optionally detecting excitation lighttransmitted through or reflected from the region of the subject; (c)detecting fluorescent light emitted from within the subject; and (d)processing data corresponding to the detected fluorescent light and theoptionally detected excitation light to provide a tomographicrepresentation of the region of the subject, wherein the processing stepcomprises (i) establishing a forward model of excitation lightpropagation from an excitation light source to the light source withinthe subject and of emission light propagation from the light source ofthe subject to a detector using the data corresponding to the optionallydetected excitation light and the detected fluorescent light, whereinone or more virtual-matching transformation(s) is/are applied to thedata corresponding to the detected fluorescent light and the datacorresponding to the detected excitation light account for a refractiveindex discontinuity (e.g., mismatch) at the surface of the subject;optionally, an intensity of the detected fluorescent light is normalizedusing an intensity of spatially-corresponding detected excitation light;and the forward model is established as a weight matrix of normalizedelements using one or more infinite homogeneous functions such thatlight propagation is modeled as if there is no discontinuity inrefractive index at the surface of the subject; and (ii) inverting theweight matrix to obtain the tomographic representation of the region ofthe subject.

In certain embodiments, the method obtains one or more tomographicimages which include a concentration map of the agent or probe in theheterogeneous diffuse object. In certain embodiments, the concentrationsfor the concentration map are determined using calibration measurementsof a phantom (physical mock-up) of the heterogeneous diffuse object.

In addition, the tomographic representation can indicate an area ofdisease within a region of the subject. Furthermore, the tomographicrepresentation can indicate an area of inflammation, arthritis, cancer,metastasis, plaque, infectious disease, cardiovascular disease,respiratory disease, metabolic disease, central nervous system disease,immune disease, neurodegenerative disease, dermatological disease,ophthalmic disease, cutaneous disease or a combination of two or more ofthe foregoing, within the region of the subject. In certain embodiments,the tomographic representation indicates a boundary of a disease site,such as a tumor within the region of the subject.

In certain embodiments, the probe used for imaging is an endogenousprobe. In other embodiments, the probe may be exogenous and administeredto the subject.

In certain embodiments, the probe comprises a member selected from thegroup consisting of a molecular probe, a fluorescent molecular probe, aphototherapy based fluorescent probe, an activatable fluorescent probe,an enzyme-activatable fluorescent probe, an activity based probe, atargeted fluorescent probe, a near-infrared fluorescent molecular probe,a fluorescent protein, a fluorescent biomolecule, a non-specificfluorescent probe, quantum dots, a receptor-targeted near-infraredfluorochrome, an antibody- or antibody-like targeted near-infraredfluorochrome, a wavelength-shifting beacon, a multi-color fluorescenceprobe, and a lanthanide metal-ligand probe. In addition, the probe maycomprise a fluorochrome attached to a delivery vehicle comprising anyone or more of a polymer, a dendrimer, a protein, a carbohydrate, alipid sphere, and a nanoparticle.

In certain embodiments, the method of imaging comprises administering tothe subject a plurality of probes having optically distinguishablefluorescent emission wavelengths, detecting fluorescent light emittedfrom each of the probes, and processing data corresponding to thedetected light to provide one or more tomographic representations. Inaddition, the effect of the probe on the region within the object may bedetermined using the tomographic representation. Furthermore, the methodmay comprise imaging at excitation and emission wavelengths of a naturaltissue chromophore.

In certain embodiments, imaging steps (b), (c), (d), and (e) may berepeated to obtain tomographic representations as a function of time. Inaddition, the kinetics of a distribution of the probe within the regioncan be monitored using tomographic representations. The kinetics ofactivation of the probe can be monitored using tomographicrepresentations.

In certain embodiments, the method may comprise imaging at excitationand emission wavelengths of a natural tissue chromophore.

In certain embodiments, the tomographic representation comprises a mapshowing quantity of the probe in three dimensions. The tomographicrepresentation may comprise one or more images, and the method mayfurther comprise storing the one or more images, displaying the one ormore images, or both storing and displaying the one or more images. Inaddition, the tomographic representation can include storing the one ormore virtually-matched images, displaying the one or morevirtually-matched images, or both story and displaying the one or morevirtually-matched images. In addition, the tomographic representationmay comprise a three-dimensional tomographic image, and the method mayfurther comprise the step of combining the three-dimensional tomographicimage with photographic, pictorial, magnetic resonance, x-ray computedtomography, ultrasound, single photon emission tomography, orpositron-emission tomography imaging data and representations.

In certain embodiments, the imaging method further comprises the step ofdetecting or monitoring a cellular abnormality or disease usingtomographic representation. The cellular abnormality or disease maycomprise at least one member selected from the group consisting ofcancer, oncological disease, infectious disease, metabolic disease,respiratory disease, cardiovascular disease, AIDS, immune disease,central nervous system disease, neurodegenerative disease, inflammation,dermatological disease, ophthalmic disease, cutaneous disease, inheriteddiseases, environmental diseases, bone-related diseases, immunologicdisease, and surgery-related complications.

In certain embodiments, the subject of the imaging method is a mammal.In certain embodiments, the subject is a human.

In certain embodiments, the probe of the imaging method may comprise anendogenous fluorophore that is encoded by a gene within the subject. Theexpression of the gene encoding the fluorophore can be determined usingtomographic representation. The endogenous fluorophore can be afluorescent protein or biomolecule, including but not limited to green,red and infrared fluorescent proteins.

In each of the foregoing, the subject can be a mammal, for example, ahuman.

In another aspect, the invention is an apparatus for reconstructing atomographic representation of a probe within a region of the subject,the apparatus comprising: a memory that stores code defining a set ofinstructions; and a processor that executes the instructions thereby to:(a) establish a forward model of excitation light propagation from anexcitation light source to the probe within the region of the subjectand of emission light propagation from the probe to a detector usingdata corresponding to detected fluorescent light from the probe andusing data corresponding to detected excitation light transmittedthrough or reflected from the region of the subject, wherein one or morevirtual-matching transformation(s) is/are applied to the datacorresponding to the detected fluorescent light and the datacorresponding to the detected excitation light to account for arefractive index discontinuity (e.g., mismatch) at the surface of thesubject; an intensity of the detected fluorescent light is normalizedusing an intensity of spatially-corresponding detected excitation light;and the forward model is established as a weight matrix of normalizedelements using one or more infinite homogeneous functions such thatlight propagation is modeled as if there is no discontinuity inrefractive index at the surface of the subject; and (b) invert theweight matrix to obtain the tomographic representation of the region ofthe subject ace.

In certain embodiments, the processor executes the instructions toestablish the forward model wherein the excitation light source isrepresented in real space, the detected fluorescent light and thedetected excitation light are represented in frequency space, and thetomographic representation of the region of the subject is arepresentation in real space.

In another aspect, the invention can also provide for a diffuse opticaltomography system comprising one or more illumination sources; anoptical imaging apparatus configured to direct light from the at leastone illumination source into a subject at a plurality of locations; adetector configured to detect at multiple locations light emanating fromthe subject to obtain a first and second measurement, wherein the firstmeasurement is a reference measurement and the second measurementcorresponds to absorption of at least a portion of the illuminatinglight as it passes through a light-absorbing region within the subject,and wherein the reference measurement does not reflect all of saidabsorption; and a processor configured to process data corresponding tothe first and second measurements of detected light emanating from thesubject, wherein the processor is configured to execute instructions to:(a) establish a forward model of light propagation from at least one ofthe one or more illumination sources to the light-absorbing regionwithin the subject and of light propagation from the region to thedetector using the data corresponding to the first and secondmeasurements, wherein one or more virtual-matching transformation(s)is/are applied to the data corresponding to the detected fluorescentlight to account for a refractive index discontinuity at the surface ofthe subject, and the forward model is established as a weight matrix ofelements using one or more infinite homogeneous functions such thatlight propagation is modeled as if there is no discontinuity inrefractive index at the surface of the subject; and (b) invert theweight matrix to obtain the tomographic representation of the region ofthe subject. In addition, the system can comprise at least twoillumination sources having different wavelengths. In certainembodiments, the at least two illumination sources are near-infraredlight sources.

In certain embodiments, a diffuse optical tomography imaging system cancomprise at least two illumination sources with different wavelengthscomprising a wavelength below an isosbestic point of an oxy-hemoglobin(HbO) and a deoxy-hemoglobin (Hb), and a wavelength above the isosbesticpoint.

In certain embodiments, step (b) of the method includes determining aconcentration (or a concentration map) of the probe in the object usingcalibration measurements of a phantom (physical mock-up) of the object.

Elements from embodiments of one aspect of the invention may be used inother aspects of the invention (e.g., elements of claims depending fromone independent claim may be used to further specify embodiments ofother independent claims). Other features and advantages of theinvention will be apparent from the following figures, detaileddescription, and the claims.

The objects and features of the invention can be better understood withreference to the drawings described below, and the claims. In thedrawings, like numerals are used to indicate like parts throughout thevarious views.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 is a schematic drawing depicting a diffusive volume V surroundedby free space, according to an illustrative embodiment of the invention.

FIG. 2 is a block diagram of the steps of a method for obtaining aquantitative 3D distribution of a fluorescing or absorbing probe,tissue, or other target object in a subject, according to anillustrative embodiment of the invention.

FIG. 3 is a schematic drawing depicting flux that leaves the subject atits surface, according to an illustrative embodiment of the invention.

FIG. 4 is a schematic drawing depicting the inverted situation where thesubject is embedded in an otherwise infinite and homogeneous diffusivemedium of identical optical properties to those of the subject,according to an illustrative embodiment of the invention.

FIG. 5 is a schematic drawing depicting the effect of virtually-matchingthe measurements to a medium with the same average optical properties ofthe subject, according to an illustrative embodiment of the invention.

FIG. 6 is a schematic drawing depicting that once the data has beenconverted to the virtually-matched expression, it can be propagatedthrough the virtual-matching diffusive medium from the surface positionto an arbitrary virtual detector, according to an illustrativeembodiment of the invention.

FIG. 7 depicts reconstructed 3D images of a mouse, comparing the virtualindex matching approach, according to an illustrative embodiment of theinvention, with conventional reconstruction.

FIG. 8 depicts reconstructed 3D images of a mouse, comparing the virtualindex matching approach, according to an illustrative embodiment of theinvention, with conventional reconstruction.

FIG. 9 depicts reconstructed 3D images of a calibration phantom,comparing the index matching approach, according to an illustrativeembodiment of the invention, with conventional reconstruction.

DETAILED DESCRIPTION

It is contemplated that methods, systems, and processes described hereinencompass variations and adaptations developed using information fromthe embodiments described herein.

Throughout the description, where systems and compositions are describedas having, including, or comprising specific components, or whereprocesses and methods are described as having, including, or comprisingspecific steps, it is contemplated that, additionally, there are systemsand compositions of the present invention that consist essentially of,or consist of, the recited components, and that there are processes andmethods of the present invention that consist essentially of, or consistof, the recited processing steps.

The mention herein of any publication, for example, in the Backgroundsection, is not an admission that the publication serves as prior artwith respect to any of the claims presented herein. The Backgroundsection is presented for purposes of clarity and is not meant as adescription of prior art with respect to any claim.

Headers are used herein to aid the reader and are not meant to limit theinterpretation of the subject matter described.

As used herein, the term “image” is understood to mean a visual displayor any data representation that may be interpreted for visual display.For example, a three-dimensional image may include a dataset of valuesof a given quantity that varies in three spatial dimensions. Athree-dimensional image (e.g., a three-dimensional data representation)may be displayed in two-dimensions (e.g., on a two-dimensional screen,or on a two-dimensional printout).

The term “tomographic image” may refer, for example, to an opticaltomographic image, an x-ray tomographic image, a tomographic imagegenerated by magnetic resonance, positron emission tomography (PET),magnetic resonance, (MR) single photon emission computed tomography(SPECT), and/or ultrasound, and any combination of these.

The term “excitation image” is understood to mean an image acquired atthe wavelength corresponding to that of the exposing light source, ofsaid exposing light emanating from the object being imaged.

The terms “fluorescence image” or “emission image” are understood tomean an image acquired at the wavelength corresponding to the emissionwavelength of a fluorescent agent or probe.

The term “residual image” is understood to mean the image resulting fromthe mathematical operation of subtracting a corrective term, for examplean image, from an original image, for example a fluorescence image.

As used herein, the term “map” is understood to mean a visual display,or any data representation that may be interpreted for visual display,which contains spatially-correlated information. For example, athree-dimensional map of a given volume may include a dataset of valuesof a given quantity that varies in three spatial dimensions throughoutthe volume, and the three-dimensional map may be displayed intwo-dimensions.

As used herein, the term “electromagnetic radiation” is understood tomean self-propagating waves in space of electric and magnetic componentsthat oscillate at right angles to each other and to the direction ofpropagation, and are in phase with each other. Electromagnetic radiationincludes: radio waves, microwaves, red, infrared, and near-infraredlight, visible light, ultraviolet light, X-rays and gamma rays.

As used herein the term “image acquisition device” includes any detectorof electromagnetic radiation including, but not limited to, CCD camera,photomultiplier tubes, photodiodes, and avalanche photodiodes.

As used herein, the term “virtually-matched” or “virtual-matching” isunderstood to mean measurements transformed through a virtual-matchingtransformation.

As used herein the term “virtual-matching method” or “virtual-matchingapproach” refers to a methodology that transforms the measurements takenat the surface of a subject surrounded by free space to the measurementsthat would exist if the subject were surrounded by a diffusive medium ofoptical properties equivalent to the average optical properties of thesubject.

As used herein the term “virtually-matched medium” refers to a mediumsurrounding the subject with the same volume as that surrounding thesubject that has the optical properties equal to the average opticalproperties of the subject.

As used herein the term “propagation of measurements” refers to thepropagation of the virtually-matched measurements to a generic point inspace outside of the subject, i.e. within the virtually-matched medium.

As used herein the term “virtual detectors” refers to the location inspace outside of the subject, i.e. within the virtually-matched medium,of the detectors to which the virtually-matched measurements arepropagated.

As used herein, the term “forward model” is understood to mean aphysical model of light propagation in a given medium from a source to adetector.

A technique is described herein for tomographic reconstruction thatperforms a transformation on the detected intensities converting theminto the virtually-matched expressions on subsets of tomographicdatasets as described herein to enable the use of infinite homogeneousfunctions (i.e. functions that do not take into account the presence ofthe boundary) and to enable the propagation of these measurements to anypoint in the virtually-matched medium in order to perform fasttomographic reconstruction prior to image display and/or analysis. Forthe purposes of illustration, an illustrative, non-limiting descriptionis provided for a method of fluorescence tomographic reconstruction invivo of objects, e.g., reporters and/or agents such as contrast agentsor probes, in a diffusive medium (e.g., a mammalian subject). Thistechnique can be used in any of the tomographic systems describedherein.

Fluorescence Molecular Tomography, abbreviated as FMT (sometimes alsoreferred to as Fluorescence Mediated Tomography) or Diffuse OpticalTomography (when used to image concentration of absorbers), abbreviatedas DOT, provide a method of in vivo imaging including the steps ofadministering to a subject an optical imaging probe; directingexcitation light into the subject at multiple locations; optionallydetecting excitation light emanating from the subject; detecting opticallight emitted from one or more probes within the subject; and processingdata corresponding to the detected fluorescent light emitted from theprobe within the subject and, optionally, the detected excitation lightemanating from the subject, to provide a tomographic representation ofthe region within the subject. The processing of data corresponding toboth the detected excitation light and detected fluorescent lightcomprises simulating photon propagation at the excitation wavelength andsimulating photon propagation at the emission wavelength to obtain aprediction of one or more quantitative measurements of the probe, suchas concentration or total accumulation in a region within the object,and can also include additional steps of applying statistical optimalestimation and coincidence masking techniques to predict and compensatefor waveguiding effects (see for example International PatentApplication No. PCT/US2008/65648 “Imaging Systems Featuring WaveguidingCompensation”). The steps can also be repeated at predeterminedintervals, thereby allowing for the evaluation of the subject over time.The subject may be a vertebrate animal, for example, a mammal, includinga human. The subject may also be a non-vertebrate (for example, C.elegans, drosophila, or another model research organism, etc.) used inlaboratory research.

In certain embodiments, the present invention can be used in FMT as wellas DOT imaging systems. DOT is a technique that offers the capability toquantify changes in absorption present in highly scattering media suchas tissue. Its theoretical principles are similar to FMT in the sensethat sources need to be scanned on the object and light detected at adetector, assuming that light diffuses within the volume. In order foran absorption perturbation to be imaged in this modality a referenceimage where light has not been absorbed or that has been absorbed in alesser manner needs to be taken. After this measurement, equivalent tothe excitation measurement in FMT, a measurement where this absorptionis present is acquired (equivalent to the emission measurement in FMT).By choosing appropriate wavelengths (e.g., in the near infrared), thistechnique may simultaneously quantify the tissue concentration of bothoxy-(HbO) and deoxy-hemoglobin (Hb), and thus the oxygen saturation andblood volume. Typically, two or more near-infrared sources, chosen onboth sides of the isosbestic point of the oxy/deoxyhemoglobin absorptionspectrum (near 800 nm) are used to illuminate the tissue at variouslocations. The light intensity distribution at the tissue surface thuscontains both spectral and spatial information about subsurfaceabsorbers.

In certain embodiments, the invention can be used within a FMT imagingsystem comprising: an excitation light source; an optical imagingapparatus configured to direct light from the excitation light sourceinto a subject at a plurality of locations; a detector configured todetect at multiple locations excitation light emanating from the subjectand fluorescent light emanating from a region within the subject; and aprocessor configured to process data corresponding to the detectedexcitation light emanating from the subject and data corresponding tothe detected fluorescent light emanating from the region of the subjectto produce a tomographic representation of the region of the subject.The processor is configured to execute instructions to establish aforward model of excitation light propagation from the excitation lightsource to the region of the subject and of fluorescent light propagationfrom the region to the detector using the data corresponding to thedetected excitation light and the detected fluorescent light. Theexcitation light source and the detected fluorescent light aretransformed into their virtual-matched expression. Optionally, thevirtually-matched measurements can then be propagated to an array ofvirtual detectors. Finally, the forward model is established as adiscretized weight matrix of normalized elements which do not need toaccount for the presence of the surface; and the weight matrix isinverted to obtain the tomographic representation of the region of thesubject in real space.

In the forward model, a surface of the subject is identified andboundary conditions are established for the surface. The boundarymeasurements are then transformed to the virtually-matched expressionscorresponding to the surface of the subject in a virtually-matchedinfinite homogeneous medium, thereby simplifying the forward model. Thedata corresponding to the surface of the subject surrounded by freespace comprises an experimental measurement of surface fluxdistribution. The forward model then models excitation light propagationfrom the excitation light source to the region of the subject andfluorescent light propagation from the region to the detector, where nowthere is no free space between the surface of the subject and thedetector and the medium has been replaced by a virtually-matched mediumwith the optical properties equal to the average optical properties ofthe subject.

In certain embodiments, the detected fluorescent light is emitted from aprobe within the region of the subject, and the forward model thenmodels excitation light propagation from the excitation light source tothe probe and emitted fluorescent light propagation from the probe tothe detector. In the forward model, a Born approximation is used toexpress an intensity of the detected fluorescent light emitted from theprobe having spatially-varying concentration within the region. Theintensity of the detected fluorescent light is normalized using anintensity of the spatially-corresponding detected excitation light.

In other embodiments, the forward model represents the detectedexcitation light and the detected fluorescent light transformed intotheir virtually-matched expressions. In the system, the excitation lightsource or the optical imaging apparatus comprises a scanner configuredto direct light into the subject at a plurality of locations, therebydefining a plurality of source locations. With the virtually-matchedexpressions, a non-uniform grid of any number of sources can be used.The detector comprises an array of detector locations which can bearbitrary or be conformed to a simple geometry such as a plane, and theforward model is established using data obtained from a plurality ofdetector locations.

In certain embodiments of the system, the excitation light isnear-infrared. The excitation light has wavelength within a range fromabout 500 nanometers to about 1000 nanometers. In other embodiments ofthe system, the excitation light has wavelength within a range fromabout 635 nanometers to about 850 nanometers. Furthermore, theexcitation light is continuous wave (CW) light. The excitation lightcomprises at least one member selected from the group consisting ofcontinuous wave light, time-resolved light, and intensity modulatedlight.

The method and algorithm accept as input raw scan images generated by afluorescence molecular tomography (FMT) system acquisition of anyobject. As described in U.S. Pat. No. 6,615,063 “Fluorescence-MediatedMolecular Tomography”, U.S. patent application Ser. No. 11/003,936“Imaging Volumes with Arbitrary Geometries in Contact and Non-ContactTomography”, and International Patent Application No. PCT/US2004/003229“Method and System for Free Space Optical Tomography of Diffuse Media”,the texts of which are incorporated herein by reference in theirentirety, FMT-generated raw scan images contain images at both theexcitation wavelength of the light source, called “excitation images”,and at the emission wavelength of the contrast agent, interchangeablycalled “emission images” or “fluorescence images”, for a multiplicity ofsource and/or detector locations. The raw scan images can be optionallypre-processed to detect and compensate for the effects of opticalheterogeneity in the medium, as described in International PatentApplication No. PCT/US2008/65648 “Imaging Systems Featuring WaveguidingCompensation”.

In preferred embodiments, the detected light preferably includesexcitation light from the light source that has been transmitted throughor reflected from the object and fluorescent light emitted from one ormore fluorophore within the object. In the case of DOT, only theexcitation light from the light source that has been transmitted throughthe object is detected. Data corresponding to the excitation lighttransmitted through or reflected from the object can be used tocorrect/calibrate captured fluorescent measurements, thereby providingmore accurate tomographic images. The one or more fluorophore emitsfluorescent light as a result of excitation by the excitation light.Background fluorescence may be accounted for by obtaining backgroundmeasurements and processing data corresponding to the capturedfluorescent light accordingly. For example, the method may include thestep of detecting a background signal, where the processing stepincludes generating a corrected measurement of the detected fluorescentlight and/or a corrected measurement of the detected excitation lightusing data corresponding to the detected background signal, and usingthe corrected measurement(s) in the optical tomographic reconstruction.In certain embodiments, the processing step includes generating acorrected measurement of the detected fluorescent light and a correctedmeasurement of the detected excitation light using data corresponding tothe detected background light, generating a calibrated fluorescentmeasurement from the corrected fluorescent measurement and the correctedexcitation light measurement, and using the calibrated fluorescentmeasurement in the optical tomographic reconstruction.

Data corresponding to the detected light may be used as input in theoptical tomographic and/or planar reconstruction, for example, in aniterative process. In certain embodiments, the steps of the method arerepeated to obtain a plurality of tomographic and/or planar images. Incertain embodiments, the steps of the method are repeated to obtaintomographic representations as a function of time. In other embodiments,the kinetics of distribution of a probe within a region are monitoredusing tomographic representations. In another aspect, the kinetics ofactivation of a probe within a region are monitored using tomographicrepresentations.

In other embodiments, the invention is a method of imaging adistribution of a fluorescent probe within a region of a subject, themethod comprising: (a) administering to the subject a probe comprising avisible or near-infrared fluorophore; (b) directing visible ornear-infrared excitation light into the subject at multiple locations toreflect from or transilluminate at least a portion of the region of thesubject containing the fluorescent probe; (c) optionally detectingexcitation light transmitted through or reflected from the region of thesubject; (d) detecting fluorescent light emitted from the probe withinthe subject; and (e) processing data corresponding to the detectedfluorescent light and the optionally detected excitation light toprovide a tomographic representation of the region of the subject,wherein the processing step comprises: (i) establishing a forward modelof excitation light propagation from an excitation light source to thelight source within the subject and of emission light propagation fromthe light source of the subject to a detector using the datacorresponding to the optionally detected excitation light and thedetected fluorescent light, wherein: (A) a surface of the subject isidentified and boundary conditions are established for the surface; (B)The surface measurements are transformed into their virtually-matchedexpressions which simulate an infinite homogeneous medium, therebysimplifying the forward problem; (C) the virtually-matched fluorescentlight and, optionally, the virtually-matched excitation light, arepropagated to a planar, or optionally, an arbitrary, configuration ofvirtual detectors, which would enable the use of fast inversionalgorithms; and (D) the forward model is established as a discretizedweight matrix of normalized elements which do not need to account forthe boundary; and (ii) inverting the weight matrix to obtain thetomographic representation of the region of the subject in real space.

In certain embodiments, the tomographic representation comprises a mapof concentration of the probe within the region of the subject. In otherembodiments, the tomographic representation comprises a map showingquantity of the probe in three dimensions. In addition, the tomographicrepresentation comprises one or more images, and wherein the methodfurther comprises storing the one or more images, displaying the one ormore images, or both storing and displaying the one or more images. Inother embodiments, the tomographic representation comprises athree-dimensional tomographic image and wherein the method furthercomprises the step of combining the three-dimensional tomographic imagewith magnetic resonance, x-ray computed tomography, ultrasound, singlephoton emission tomography, or positron emission tomography imagingdata.

In certain embodiments, the probe used for imaging is an endogenousprobe. Furthermore, the probe may comprise an endogenous fluorophorethat is encoded by a gene within the subject. In other embodiments, theinvention is a method for determining expression of the gene encodingthe fluorophore using the tomographic representation. In otherembodiments, the endogenous fluorophore is a fluorescent protein orbiomolecule. In other embodiments, the invention is a method comprisingthe step of imaging at excitation and emission wavelengths of a naturaltissue chromophore.

In other embodiments, the probe used for imaging is administered to thesubject. In certain embodiments, the invention includes methods forimaging with probes wherein step (a) comprises administering to thesubject a plurality of probes having optically distinguishablefluorescent emission wavelengths, step (d) comprises detectingfluorescent light emitted from each of the probes, and step (e)comprises processing data corresponding to the detected light to provideone or more tomographic representations. In other embodiments, theinvention is used to determine an effect of the probe on the regionwithin the object using the tomographic representation. The probecomprises a member selected from the group consisting of a molecularprobe, a fluorescent molecular probe, an activatable fluorescent probe,an enzyme-activatable fluorescent probe, a targeted fluorescent probe, anear-infrared fluorescent molecular probe, a fluorescent protein, afluorescent biomolecule, a non-specific fluorescent probe, quantum dots,a receptor-targeted near-infrared fluorochrome, an antibody-targetednear-infrared fluorochrome, a wavelength-shifting beacon, a multi-colorfluorescence probe, and a lanthanide metal-ligand probe. In otherembodiments, the probe comprises a fluorochrome attached to a deliveryvehicle comprising any one or more of a polymer, a dendrimer, a protein,a carbohydrate, a lipid sphere, and a nanoparticle.

In another aspect, the invention relates to a method of imaging a targetvolume of an object, the method including the steps of directingexcitation radiation into the object at multiple locations; optionallydetecting excitation radiation transmitted through or reflected from theobject; detecting radiation at a surface of the object; detectingradiation emitted from one or more contrast agents/probes within theobject; and processing data corresponding to the detected radiationtransmitted through or reflected from the object, the optionallydetected excitation radiation transmitted through or reflected from theobject, and the detected radiation emitted from the one or more contrastagents/probes within the object to provide one or more images of thetarget volume of the object. The method may further include the step ofdisplaying the image. The object may be, for example, an animal, forexample, a mammal, or a human.

In another aspect, the invention relates to a method for detectingdisease. In certain embodiments, the tomographic representationindicates an area of disease within the region of the subject. In otherembodiments, the tomographic representation indicates an area ofarthritis, cancer, metastasis, plaque, or a combination of two or moreof the foregoing, within the region of the subject. In otherembodiments, the tomographic representation indicates a boundary of atumor within the region of the subject. In other embodiments, thetomographic representation can be used to detect or monitor a cellularabnormality or disease. Furthermore, the cellular abnormality or diseasecomprises at least one member selected from the group consisting ofcardiovascular disease, AIDS, neurodegenerative disease, inflammation,dermatological disease, ophthalmic disease, cutaneous disease, andimmunologic disease.

Algorithms that support preferred embodiments of the invention aredetailed below. FIG. 1 is a schematic drawing depicting a diffusivevolume V 101 surrounded by Free space, i.e. an otherwise infinitehomogeneous and non-diffusive medium 102. The geometry shown in FIG. 1,consists of a diffusive volume V 101 bounded by surface S, whichseparates it from an outer non-diffusive medium 102 of refractive indexn_(out). The diffusive medium is characterized by its absorptioncoefficient μ_(a), its reduced scattering coefficient μ_(s)′ (defined asμ_(s)′=μ_(s)(1−g), where g is the anisotropy factor), and its averagerefractive index n_(in). In a highly absorbing and scattering medium thediffusion coefficient may be defined as D=1/3(μ_(s)′+αμ_(a)), the factorα depending non-linearly on the optical properties and having typicallyvalues between α=0.2 to α=0.6 (see Ripoll, J., D. Yessayan, et al.(2004). “Experimental determination of photon propagation in highlyabsorbing and scattering media.” J. Opt. Soc. Am. A 22(3) and referencestherein for a deeper study of this factor and experimental validation).Typical values of α for tissue in the visible (where tissue absorptionis greater) are in the order of α=0.5 for typical values of anisotropyin tissue of g˜0.8. In preferred embodiments, the invention dealsdirectly with D and μ_(a), instead of μ_(s)′ and μ_(a), assuming theyare related through the above mentioned expression. Additionally, allderivation is done in the frequency domain, with the extrapolation totime-domain through a Fourier transform, or to the CW regime bystraightforward selection of the zero frequency component.

Assume that in the volume V 101 of FIG. 1, a point source located atr_(s) inside the medium whose intensity is modulated at a frequency ω.In this case, the average intensity U may be expressed as U(r,t)=U(r)exp[−iωt]. Accounting for energy conservation in the Radiative TransferEquation, the U detected at r within V represents a diffuse photondensity wave (DPDW) and obeys the Helmholtz equation:

$\begin{matrix}{{{{\nabla^{2}{U(r)}} + {\kappa_{0}^{2}{U(r)}}} = {{{- \frac{S(r)}{D}}r} \in V}},} & (1)\end{matrix}$with a complex wave-number κ₀ given by:

$\begin{matrix}{\kappa_{0} = \left( {{- \;\frac{\mu_{a}}{D}} + {{\mathbb{i}}\frac{\omega\; n_{i\; n}}{cD}}} \right)^{1/2}} & (2)\end{matrix}$where c is the speed of light in vacuum and S(r) is the sourcedistribution. In an infinite homogeneous 3D medium the Green functionaccounting for light propagation from source to detector is given by:

$\begin{matrix}{{g\left( {\kappa_{0}{{r_{s} - r_{d}}}} \right)} = \frac{\exp\left( {{\mathbb{i}}\;\kappa_{0}{{r_{s} - r_{d}}}} \right)}{D{{r_{s} - r_{d}}}}} & (3)\end{matrix}$

Taking into account rigorously the boundary S, the average intensityU^(srf) inside volume V which takes into account the presence of theboundary is found through Green's theorem as [J. Ripoll and M.Nieto-Vesperinas, J. Opt. Soc. Am. A 16, 1453 (1999)]:

$\begin{matrix}{{{U^{srf}\;\left( r_{d} \right)} = {{U^{({inc})}\left( r_{d} \right)} - {\frac{1}{4\pi}{\int_{S}{\left\lbrack {{{U^{srf}\left( r^{\prime} \right)}\frac{\partial{g\left( {\kappa{{r^{\prime} - r_{d}}}} \right)}}{\partial{\hat{n}}^{\prime}}} - {{g\left( {\kappa{{r^{\prime} - r_{d}}}} \right)}\frac{\partial{U^{srf}\left( r^{\prime} \right)}}{\partial{\hat{n}}^{\prime}}}} \right\rbrack{\mathbb{d}S^{\prime}}}}}}},\mspace{20mu}{where}} & (4) \\{\mspace{20mu}{{U^{({inc})}(r)} = {\int_{V}{{S(r)}{g\left( {\kappa_{0}{{r_{s} - r_{d}}}} \right)}{\mathbb{d}^{3}r}}}}} & (5)\end{matrix}$is the average intensity that is obtained in the absence of the surface.One can use Fick's Law:

$\begin{matrix}{{J_{n}(r)} = {{{J(r)} \cdot \hat{n}} = {{- D}\frac{\partial{U^{srf}(r)}}{\partial\hat{n}}}}} & (6)\end{matrix}$and the boundary condition between the diffusive and non-diffusivemedium (R. Aronson, J. Opt. Soc. Am. A 12, 2532 (1995)):

$\begin{matrix}{{{{U^{srf}(r)}{_{S}{= {{- C_{nd}}D\frac{\partial{U^{srf}(r)}}{\partial\hat{n}}}}}_{S}},{r \in S}}{{{U^{srf}(r)}{_{S}{= {C_{nd}{J_{n}(r)}}}}_{S}},{r \in S}}} & (7)\end{matrix}$where the coefficient C_(nd) takes into account the refractive indexmismatch between both media (R. Aronson, J. Opt. Soc. Am. A 12, 2532(1995)). In the case of index matched media, i.e. n_(out)=n_(in),C_(nd)=2, whereas for typical tissue/air index values (nin=1.333,nout=1) C_(nd)˜5. Making use of Eqs. (6) and (7) in Eq. (4), there is aconvenient expression which depends solely on the total flux J_(n) sothat Eq. (4) can be rewritten as:

$\begin{matrix}{{{U^{srf}(r)} = {{U^{({inc})}(r)} + {\frac{1}{4\pi\; D}{\int_{S}{\left\lbrack {{C_{nd}D\frac{\partial{g\left( {\kappa{{r^{\prime} - r}}} \right)}}{\partial n^{\prime}}} + {g\left( {\kappa{{r^{\prime} - r}}} \right)}} \right\rbrack{J_{n}\left( r^{\prime} \right)}\ {\mathbb{d}S^{\prime}}}}}}},\mspace{79mu}{r \in V}} & (8)\end{matrix}$

In order to simplify further derivations, the surface integral Σ⁺(J_(n))is defined as the surface contribution of the measured flux J_(n) asfollows:

$\begin{matrix}{{{\sum\limits^{+}\;\left( J_{n} \right)} = {\frac{1}{4\pi\; D}{\int_{S}{\left\lbrack {{C_{nd}D\frac{\partial{g\left( {\kappa{{r^{\prime} - r}}} \right)}}{\partial n^{\prime}}} + {g\left( {\kappa{{r^{\prime} - r}}} \right)}} \right\rbrack{J_{n}\left( r^{\prime} \right)}\ {\mathbb{d}S^{\prime}}}}}},\mspace{79mu}{r \in V}} & (9)\end{matrix}$

In terms of Eq. (8) we may write the average intensity at the boundaryU^(srf) which takes into account the interface and the general surface Sas:U ^(srf)(r)=U ^((inc))(r)+Σ⁺(J _(n))  (10)

Eq. (9) represents the average intensity accounting for the presence ofthe surface S.

Consider now the case where instead of having the volume V 101surrounded by free space (see FIG. 5), the same volume is surrounded bya medium with the same optical properties as those of the diffusiveobject of volume V, i.e. D, μ_(a), and n _(in). In this case, theaverage intensity would not reflect the presence of the boundary, sinceby having a medium surrounding volume V of the same properties, theoptical discontinuity-generated boundary effect would disappear. Theexpression accounting for this is referred to in the presentspecification as the virtually-matched expression. This expression isdetermined from the surface-dependent expression in Eq. (10). In orderto do this, note that the virtually-matched case shown in FIG. 5 can bereduced to the sum of the actual measurement FIG. 1 with its invertedsituation, FIG. 4. That is, if the contribution of the missing volume isadded to the surface-dependent expression Eq. (10), the averageintensity that would be present in the absence of the surface isobtained. The contribution of the volume that surrounds the subject Vthat yields the virtually-matched average intensity is given by:

$\begin{matrix}{{{\sum\limits^{-}\;\left( J_{n} \right)} = {{{- \frac{1}{4\pi\; D}}{\int_{S}{\left\lbrack {{C_{nd}D\frac{\partial{g\left( {\kappa{{r^{\prime} - r}}} \right)}}{\partial n^{\prime}}} + {g\left( {\kappa{{r^{\prime} - r}}} \right)}} \right\rbrack{J_{n}\left( r^{\prime} \right)}\ {\mathbb{d}S^{\prime}}}}} + \sum\limits^{(\infty)}}}\;} & (11)\end{matrix}$where Σ^((∞)) represents the surface integral at a sphere of infiniteradius, which as long as μ_(a)>0 becomes Σ^((∞))=0, since the Greenfunction at infinity is zero. Note that the minus sign in Eq. (11) comesfrom the fact that now J_(n) and the surface normal n point in oppositedirections. Using Eq. (11), the virtual-matched solution U^(VM), i.e.the average intensity that would be present in the absence of theinterface would be given by:U ^(VM)(r)=U ^(srf)+Σ⁻(J _(n))  (12)

Making use of the boundary conditions which relate the measured fluxJ_(n) to the surface-dependent average intensity U^(srf) Eq. (12) may berewritten as:U ^(VM)(r)=C _(nd) J _(n)+Σ⁻(J _(n))  (13)

In order to demonstrate that this expression is equivalent to theaverage intensity that would exist in the absence of the interface,substitute Eq. (12) into Eq. (10) to obtain:U ^(VM)(r)=U ^(srf)(r)+Σ⁻(J _(n))=U ^((inc))(r)+Σ⁻(J _(n))+Σ⁺(J _(n))U ^(VM)(r)=U ^((inc))(r)  (14)since Σ⁺(J_(n)) and Σ⁻(J_(n)) cancel out. Rewriting explicitly Eq. (13),the virtual-matching transformation is expressed as:

$\begin{matrix}{{U^{VM}(r)} = {{C_{nd}J_{n}} - {\frac{1}{4\pi\; D}{\int_{S}{\left\lbrack {{C_{nd}D\frac{\partial{g\left( {\kappa{{r^{\prime} - r}}} \right)}}{\partial n^{\prime}}} + {g\left( {\kappa{{r^{\prime} - r}}} \right)}} \right\rbrack{J_{n}\left( r^{\prime} \right)}\ {\mathbb{d}S^{\prime}}}}}}} & (15)\end{matrix}$

It is important to note that in the virtual-matching expression shown inEq. (15), J_(n) are the actual measurements obtained from the detector,once the free-space propagation contribution has been taken intoaccount. There is therefore no need to solve the integral Eq. (8) whereone usually either solves for the surface flux J_(n) or for the averageintensity U at the boundary, as is typically achieved by using accuratealgorithms such as the Diffuse Reflectance Boundary Method (Ripoll, J.and V. Ntziachristos (2003), “Iterative boundary method for diffuseoptical tomography.” J. Opt. Soc. Am. A 20(6): 1103-1110.) orapproximations to it such as the Kirchhoff Approximation (Ripoll, J., V.Ntziachristos, et al. (2001), “The Kirchhoff Approximation for diffusivewaves.” Phys. Rev. E 64: 051917: 1-8.). Note that all the Greenfunctions, g, involved in Eq. (8) are infinite Green's functions.

Considering that the measurements at our detector are given by J_(n)^(meas), it is known that these are related to the flux at the surfaceJ_(n) as:J _(n) ^(meas)(r _(d))=J _(n)(r)f _(air)(r−r _(d)),rεS  (16)where f_(air) is a function which takes into account diffuse lightpropagation in free space, as shown in Ripoll and Ntziachristos (2006)“From finite to infinite volumes: removal of boundaries in diffuse waveimaging.” Phys. Rev. Lett. 96(17): 173903 and International PatentApplication No. PCT/US2004/003229 “Method and System for Free SpaceOptical Tomography of Diffuse Media”. Note that f_(air) becomes aconvolution with J_(n) in the more general case where out-of-focusmeasurements are included, which is not shown here, but is included inthe present invention. Eq. (16) can be applied to Eq (15).

Having determined the virtual-matching transformation, Eq. (15),consider the special instance where we want the location of thedetectors (currently on the surface S by using Eq. (16)) to be on ageneric plane within the virtually-matched medium. To that end the firstRayleigh-Sommerfeld integral formula is used, which states that for aflat surface A at z=z₀ the field (in this case the average intensity) atz>z₀ is given by (Born and Wolf, Principles of Optics):

$\begin{matrix}{{{U(r)} = {\frac{1}{2\pi}{\int_{A}{{U\left( r^{\prime} \right)}\frac{\partial{g\left( {\kappa{{r - r^{\prime}}}} \right)}}{\partial z^{\prime}}\ {\mathbb{d}A^{\prime}}}}}},{\forall{z > z_{o}}}} & (17)\end{matrix}$where A in this case is in the (xy) plane in order for Eq. (17) to bevalid. In general terms we may rewrite Eq. (17) for thevirtually-matched expression U^(VM) for a generic surface with surfacenormal n as:

$\begin{matrix}{{U_{prop}^{VM}\left( r_{d} \right)} = {\frac{1}{2\pi}{\int_{S}{{U^{VM}\left( r^{\prime} \right)}\frac{\partial{g\left( {\kappa_{0}{{r - r^{\prime}}}} \right)}}{\partial n^{\prime}}{\mathbb{d}S^{\prime}}}}}} & (18)\end{matrix}$where U_(prop) ^(VM)(r_(d)) now stands for the virtual-matchedexpression propagated to virtual detectors located at r_(d). Note thatEq. (18) only holds for values outside of volume V. Additionally, thisexpression is exact for a plane surface, and represents an approximationin the more general case. The exact expression would be such that (seeEq. (4) for comparison):

$\begin{matrix}{{U_{prop}^{VM}\left( r_{d} \right)} = {\frac{1}{2\pi}{\int_{S}{\left\lbrack {{{U^{VM}\left( r^{\prime} \right)}\frac{\partial{g\left( {\kappa_{0}{{r - r^{\prime}}}} \right)}}{\partial n^{\prime}}} + {\frac{1}{D}{g\left( {\kappa_{0}{{r - r^{\prime}}}} \right)}{J^{VM}\left( r^{\prime} \right)}}} \right\rbrack{\mathbb{d}S^{\prime}}}}}} & (19)\end{matrix}$where we have made use of Fick's law, Eq. (7). However, the quantityJ^(VM) is unknown, since we can only recover U^(VM) from ourmeasurements. In any case it should be noted that within the diffusionapproximation J^(VM)<<U^(VM) as shown in Ishimaru, Ishimaru (1978), Wavepropagation and scattering in Random Media, New York, Academic. Thus,Eq. (18) is a good approximation even in the presence of arbitraryinterfaces.

Once the virtual-matching transformation Eq. (15) is defined and theexpression that enables the propagation of these virtually-matchedvalues to any point in space outside of volume V is determined using Eq.(19), these may be applied to the fluorescence and excitationmeasurements in order to solve the inverse problem.

Assume that within volume V 601 of FIG. 6 there is a collection offluorophores with spatially-dependant concentration F(r). Thefluorescence intensity due to a collection of fluorophores withconcentration F(r) distributed within a volume V in an otherwiseinfinite homogeneous medium may be expressed within the Bornapproximation as:U _(fl)(r _(s) ,r _(d))=∫_(V) U ^(srf)(r _(s) ,r)F(r)G(r,r _(d))dr  (20)where G is the Green's function that takes into account the surface ofvolume V. Applying the virtual-matching transformation, we may rewriteEq. (20) as:U _(fl) ^(VM)(r _(s) ,r _(d))=∫_(V) U ^(srf)(r _(s) ,r)F(r)g(r,r_(d))dr  (21)where now g represents the infinite homogeneous green's function givenby Eq. (3) and U_(fl) ^(VM)(r_(s),r_(d)) could include the propagationto virtual detectors or correspond to the value of the virtual-matchedexpression at the surface of the subject. The normalized Born expression(see for example Ntziachristos and Weissleder (2001) “Experimentalthree-dimensional fluorescence reconstruction of diffuse media using anormalized Born approximation.” Opt. Lett. 26(12): 893-895) for thevirtually-matched expressions will be therefore given by:

$\begin{matrix}{{U_{n}^{VM} = {\frac{U_{fl}^{VM}\left( {r_{s},r_{d}} \right)}{U_{ex}^{VM}\left( {r_{s},r_{d}} \right)} = {\int_{V}\frac{{U^{srf}\left( {r_{s},r} \right)}{F(r)}{g\left( {r,r_{d}} \right)}{\mathbb{d}r}}{{S_{0}\left( r_{s} \right)}{g\left( {r_{s},r} \right)}}}}}\ } & (22)\end{matrix}$where we have written:U _(ex) ^(VM)(r _(s) ,r _(d))=U ^((inc))(r _(s) ,r _(d))=S ₀(r _(s))g(r_(s) ,r _(d))  (23)with S₀ being the excitation source strength. In Eq. (22) the averageintensity inside volume V, U^(srf) is given by Eq. (4).:U ^(srf)(r _(s) ,r)=U ^((inc))(r _(s) ,r)+Σ_(V)(U ^(srf))  (24)where we have written Σ_(V)(U^(srf)) as:

$\begin{matrix}{{{\sum\limits_{V}\;\left( U^{srf} \right)} = {{U^{({inc})}(r)} - {\frac{1}{4\pi}{\int_{S}{\left\lbrack {{{U^{srf}\left( r^{\prime} \right)}\frac{\partial{g\left( {\kappa{{r^{\prime} - r_{d}}}} \right)}}{\partial{\hat{n}}^{\prime}}} - {{g\left( {\kappa{{r^{\prime} - r}}} \right)}\frac{\partial{U^{srf}\left( r^{\prime} \right)}}{\partial{\hat{n}}^{\prime}}}} \right\rbrack{\mathbb{d}S^{\prime}}}}}}},{r \in V}} & (25)\end{matrix}$

Introducing Eq. (25) into Eq. (22) we obtain the virtually-matchedexpression for the normalized Born approximation:

$\begin{matrix}{U_{n}^{VM} = {\frac{U_{fl}^{VM}\left( {r_{s},r_{d}} \right)}{U_{ex}^{VM}\left( {r_{s},r_{d}} \right)} = {{\int_{V}{\frac{{g\left( {r_{s},r} \right)}{F(r)}{g\left( {r,r_{d}} \right)}}{g\left( {r_{s},r} \right)}\ {\mathbb{d}r}}} + {\int_{V}{\sum\limits_{V}\;{\left( U^{srf} \right)\frac{{F(r)}{g\left( {r,r_{d}} \right)}}{{S_{0}\left( r_{s} \right)}{g\left( {r_{s},r} \right)}}{\mathbb{d}r}}}}}}} & (26)\end{matrix}$

Equation (26) is general and takes into account all possiblecontributions of the surface S. However, for practical applications thesecond term in Eq. (26) can be neglected since the contribution to theleading term is less than 10%, reaching a much more manageableexpression for the normalized Born approximation for virtually-matchedmeasurements:

$\begin{matrix}{U_{n}^{VM} = {\frac{U_{fl}^{VM}\left( {r_{s},r_{d}} \right)}{U_{ex}^{VM}\left( {r_{s},r_{d}} \right)} \approx {\int_{V}{\frac{{g\left( {r_{s},r} \right)}{F(r)}{g\left( {r,r_{d}} \right)}}{g\left( {r_{s},r} \right)}\ {\mathbb{d}r}}}}} & (27)\end{matrix}$

By following Eq. (27) it is now possible to make use of infinitehomogeneous green's functions to solve our inverse problem:

$\begin{matrix}{{U_{n}^{VM}\left( {r_{s},r_{d}} \right)} = {\sum\limits_{i = 1}^{N}\;{{W\left( {r_{s};r_{d};r_{i}} \right)}{F\left( r_{i} \right)}}}} & (28)\end{matrix}$where W is the weight matrix:

$\begin{matrix}{{W\left( {r_{s};r_{d};r_{i}} \right)} = {\frac{1}{4\pi\; D}\left\lbrack \frac{{g\left( {r_{s},r_{i}} \right)}{g\left( {r_{i},r_{d}} \right)}\Delta\; V}{g\left( {r_{s},r_{d}} \right)} \right\rbrack}} & (29)\end{matrix}$

In order to obtain a 3D reconstruction of fluorescent agentconcentration, or of absorber concentration, we need to solve for:[F _(m)]_(1×M) =[W _(s,i) ^(m)]_(M×(N) _(s) _(×N) _(d) ₎ ⁻¹ [U _(n)^(VM(s,i))]  (30)where m is the voxel index for a total of M voxels, s is the sourceindex for a total of Ns external sources and i is the detector index fora total of Nd detectors.

There are several approaches that can be used to solve Eq. (30).Examples of approaches that could be used for solving for theconcentration of fluorescent agent or absorbers, F are iterativeapproaches (such as the Algebraic Reconstruction Technique), SingularValue Approaches (Singular Value Decomposition, TikhonoffRegularization, etc), Gradient Methods, etc. The weight matrix has asimplified expression due to the use of infinite homogeneous functions,enabling faster inversion.

FIG. 2 is a block diagram of the steps of a method for obtaining aquantitative 3D distribution of a fluorescing or absorbing probe,tissue, or other target object in a subject, according to anillustrative embodiment of the invention. This block diagram comparesthe steps used in preferred embodiments of this invention aftervirtual-matching transformation on the surface data 203 (e.g.,conforming the detectors to a planar array 204 in order to use theHybrid Inversion approach 205) with those used in a conventional imagingapproach using infinite homogenous functions to invert the problem 206.First, measurement data 201 is obtained, then surface geometry ismeasured or approximated 202 and virtual matching 203 is performed asdescribed herein above. Then, in preferred embodiments, detectors areconformed to a plane 204 such that either the Hybrid Inversion approach205 can be used, or infinite homogeneous functions for a plane are used.Where detectors are not conformed to a plane, infinite homogeneousfunctions may be solved for an arbitrary shape 206, although computationtime may be considerably higher.

FIG. 3 depicts the flux 301 that leaves the subject at its surface. Theflux 301 is then measured by the detector after it travels through Freespace 302. The flux 301 at the boundary is produced by an averageintensity 303 propagating inside the subject that was generated by asource or collection of sources or fluorophores.

FIG. 4 depicts the inverted situation from FIG. 2, where now the subjectis embedded in an otherwise infinite and homogeneous diffusive medium401 of identical optical properties to those of the subject where nowthe volume occupied by the subject is non-scattering, i.e. Free space402, and now we have a flux propagating into the diffusive medium 403.

FIG. 5 is a schematic showing the effect of virtually-matching themeasurements 502, to a medium with the same average optical propertiesof the subject 501, with the sources 503 in the same original position.The solution to this problem is equivalent to solving for the sourcepositions 503 in the absence of a boundary.

FIG. 6 is a graph illustrating how once the data has been converted tothe virtually-matched expression 601 it can be propagated through thevirtual-matching diffusive medium from the surface position 602 to anarbitrary virtual detector 603. By projecting all values from a complexsurface to a simple geometry such as a plane, other fast inversionapproaches such as the Hybrid Inversion approach can be used to recoverthe 3D distribution of the fluorophores, for example.

Illustrative examples of tomographic reconstructions performed with thebenefit of the virtual index-matching approach are shown in FIGS. 7-9.FIG. 7 shows examples of reconstructions performed on adult female Nu/Numice injected with the 4T1 model of breast cancer in the mammary fatpads. Mammary tumors and liver are imaged with the agent ProSense 750 onthe FMT 2500 Imaging System (both commercially available through VisEnMedical, Bedford, Mass.). Reconstructed images of mice in panel 701 areobtained with conventional tomographic reconstruction techniques at acomputational time of 20 minutes. Reconstructed images of mice in panel702 are obtained with the virtual index-matching approach at acomputational time of 2 minutes.

FIG. 8 shows examples of reconstructions performed on female, adult,nude mice. Spine and hips are imaged with the agent OsteoSense 680 usingthe FMT 2500 Imaging System (both commercially available through VisEnMedical, Bedford, Mass.). Reconstructed images of mice in panel 801 areobtained with conventional tomographic reconstruction techniques at acomputational time of 17 minutes. Reconstructed images of mice in panel802 are obtained with the virtual index-matching approach at acomputational time of 1 minute.

FIG. 9 shows examples of reconstructions performed in vitro on phantomsusing free dye and the FMT2500 (commercially available through VisEnMedical, Bedford, Mass.). Reconstructed images of the phantom in panel901 are obtained with conventional tomographic reconstruction techniquesat a computational time of 8 minutes. Reconstructed images of thephantom in panel 902 are obtained with the virtual index-matchingapproach at a computational time of 0.5 minutes. The images of FIGS. 7-9depict the improved, shorter computational time of the virtualindex-matching approach compared to conventional reconstructiontechniques.

In certain embodiments, the methods of the present invention are usefulwith optical imaging modalities and measurement techniques including,but not limited to: endoscopy; fluorescence endoscopy; luminescenceimaging; bioluminescence tomography, time resolved transmittanceimaging; transmittance imaging; nonlinear microscopy; confocal imaging;acousto-optical imaging; photoacoustic imaging; reflectancespectroscopy; spectroscopy; coherence interferometry; interferometry;optical coherence tomography; diffuse optical tomography andfluorescence mediated molecular tomography (continuous wave, time domainfrequency domain systems and early photon), and measurement of lightscattering, absorption, polarization, luminescence, fluorescencelifetime, quantum yield, and quenching.

Commercially available systems that can be used to employ the systemsand methods described herein include, but are not limited to, thefollowing: eXplore Optix™, Optix® and SoftScan® (ART—Advanced ResearchTechnologies, Canada), NightOWL® II LB (Berthold Technologies, Germany),NanoSPECT™, NanoPET/CT™ and HiSPECT® (Bioscan, Washington, D.C.), PhotonImager™, Beta Imager™, Micro Imager, Gamma Imager (Biospace Lab,France), Maestro® FLEX and Nuance® FLEX (Cambridge Research andInstrumentation—Cri®, Woburn, Mass.), LightSpeed™, BrightSpeed™ and MRSigna® Series, eXplore Series, Triumph™ (GE® Healthcare, UnitedKingdom), Kodak® In-Vivo Imaging FX Systems, Kodak® In-VivoMultispectral Imaging FX Systems and Kodak® Image Station 4000 series(KODAK® and Carestream®, Rochester, N.Y.), Aquacosmos® (Hamamatsu,Japan), CTLM® and LILA Imaging Systems (Imaging Diagnostic Systems—IMDS,Plantation, Fla.), Odyssey® Infrared Imaging System, Pearl® Imager(LI-COR, Lincoln, Nebr.), IMRIS® Neuro System (IMRIS®, Canada),Cellvizio® (Mauna Kea Technologies, France), SPY® and SPY®-TMR Systems,HELIOS™, LUNA™, PINPOINT®, and OPTTX® Imaging Systems (Novadaq, Canada),DYNOT Imaging System (NIRx, Glen Head, N.Y.), OV100 and IV100 (OlympusCorporation, Japan), Lumazone® (Photometrics, Tucson, Ariz.), and IVIS®Systems, IVIS® 3D, IVIS® Kinetics, IVIS® Spectrum and IVIS® Lumina(Xenogen®, Alamaeda, Calif. and Caliper® Life Sciences, Hopkinton,Mass.), iBox® (UVP, Upland, Ca), and VisEn FMT-1, VisEn FMT 1500™, andVisEn FMT 2500™ LX (VisEn™ Medical, Bedford, Mass.).

Systems of the invention may include a computer which executes softwarethat controls the operation of one or more instruments, and/or thatprocesses data obtained by the system. The software may include one ormore modules recorded on machine-readable media such as magnetic disks,magnetic tape, CD-ROM, and semiconductor memory, for example. Themachine-readable medium may be resident within the computer or can beconnected to the computer by a communication link (e.g., access viainternet link). However, in alternative embodiments, one can substitutecomputer instructions in the form of hardwired logic for software, orone can substitute firmware (i.e., computer instructions recorded ondevices such as PROMs, EPROMS, EEPROMs, or the like) for software. Theterm machine-readable instructions as used herein is intended toencompass software, hardwired logic, firmware, object code and the like.

The computer is preferably a general purpose computer. The computer canbe, for example, an embedded computer, a personal computer such as alaptop or desktop computer, or another type of computer, that is capableof running the software, issuing suitable control commands, and/orrecording information in real-time. The computer may include a displayfor reporting information to an operator of the instrument (e.g.,displaying a tomographic image), a keyboard for enabling the operator toenter information and commands, and/or a printer for providing aprint-out, or permanent record, of measurements made by the system andfor printing diagnostic results, for example, for inclusion in the chartof a patient. In certain embodiments, some commands entered at thekeyboard enable a user to perform certain data processing tasks. Incertain embodiments, data acquisition and data processing are automatedand require little or no user input after initializing the system.

In certain embodiments, the invention features an in vivo imaging methodfor selectively imaging a subject containing two or more imaging probessimultaneously, wherein two or more imaging probes are administered to asubject, either at the same time or sequentially. The imaging probes canbe any combination of optical or other imaging agents. A single imagingagent may serve as both an optical and other imaging modality agent,e.g., dual imaging agent. The method therefore allows the recording ofmultiple biological processes, functions or targets. The methods of theinvention can be used to determine a number of indicia, includingtracking the localization of the imaging probes in the subject over timeor assessing changes or alterations in the metabolism and/or excretionof the imaging probes in the subject over time. The methods can also beused to follow therapy for such diseases by imaging molecular events andbiological pathways modulated by such therapy, including but not limitedto determining efficacy, optimal timing, optimal dosing levels(including for individual patients or test subjects), pharmacodynamicparameters, and synergistic effects of combinations of therapy.

In certain embodiments, this invention can be used with other imagingapproaches such as the use of devices including but not limited tovarious scopes (microscopes, endoscopes), catheters and optical imagingequipment, for example computer based hardware for tomographicpresentations.

The invention can be used to help a physician, surgeon, or other medicalpersonnel to identify and characterize areas of disease, such asarthritis, cancers, metastases or vulnerable or unstable plaque, todistinguish diseased and normal tissue, such as detecting tumor marginsthat are difficult to detect.

The methods of the invention can also be used in the detection,characterization and/or determination of the localization of a disease,especially early disease, the severity of a disease or adisease-associated condition, the staging of a disease, and monitoringand guiding various therapeutic interventions, such as surgicalprocedures, and monitoring and/or development of drug therapy anddelivery, including cell based therapies. The methods of the inventioncan also be used in prognosis of a disease or disease condition. Withrespect to each of the foregoing, examples of such disease or diseaseconditions that can be detected or monitored (before, during or aftertherapy) include inflammation (for example, inflammation caused byarthritis, for example, rheumatoid arthritis), cancer (for example,colorectal, ovarian, lung, breast, prostate, cervical, testicular, skin,brain, gastrointestinal, pancreatic, liver, kidney, bladder, stomach,leukemia, mouth, esophageal, bone, including metastases), cardiovasculardisease (for example, atherosclerosis and inflammatory conditions ofblood vessels, ischemia, stroke, thrombosis, disseminated intravascularcoagulation), dermatologic disease (for example, Kaposi's Sarcoma,psoriasis, allergic dermatitis), ophthalmic disease (for example,macular degeneration, diabetic retinopathy), infectious disease (forexample, bacterial, viral, fungal and parasitic infections, includingAcquired Immunodeficiency Syndrome, Malaria, Chagas Disease,Schistosomiasis), immunologic disease (for example, an autoimmunedisorder, lymphoma, multiple sclerosis, rheumatoid arthritis, diabetesmellitus, lupus erythematosis, myasthenia gravis, Graves disease),central nervous system disease (for example, a neurodegenerativedisease, such as Parkinson's disease or Alzheimer's disease,Huntington's Disease, amyotrophic lateral sclerosis, prion disease),inherited diseases, metabolic diseases, environmental diseases (forexample, lead, mercury and radioactive poisoning, skin cancer),bone-related disease (for example, osteoporosis, primary and metastaticbone tumors, osteoarthritis), neurodegenerative disease, andsurgery-related complications (such as graft rejection, organ rejection,alterations in wound healing, fibrosis or other complications related tosurgical implants). The methods of the invention can therefore be used,for example, to determine the presence of tumor cells and localizationand metastases of tumor cells, the presence and localization ofinflammation, including the presence of activated macrophages, forinstance in atherosclerosis or arthritis, the presence and localizationof vascular disease including areas at risk for acute occlusion (e.g.,vulnerable plaques) in coronary and peripheral arteries, regions ofexpanding aneurysms, unstable plaque in carotid arteries, and ischemicareas, and stent thrombosis. The methods and compositions of theinvention can also be used in identification and evaluation of celldeath, injury, apoptosis, necrosis, hypoxia and angiogenesis. Themethods and compositions of the invention can also be used in formonitoring trafficking and localization of certain cell types, includingT-cells, tumor cells, immune cells, stem cells, and other cell types. Inparticular, this method may be used to monitor cell based therapies. Themethods and compositions of the invention can also be used as part ofphotodynamic therapy, including imaging, photoactivation and therapymonitoring.

In certain embodiments, the systems and methods described herein can beused to image endogenous fluorescence in a subject. For example, a geneencoding a fluorescent protein, such as green, red or infraredfluorescent protein, can be included adjacent to a gene of interest thatis to be expressed in an animal or human subject using standard genetherapy and transgenic techniques. The expression of the gene ofinterest can be determined indirectly by imaging the fluorescentprotein. If this protein is expressed, then the gene of interest hasalso been expressed. Fluorescence properties of endogenous fluorescentproteins are described in Giepmans et al., Science, 312: 217-224, 2006;Shaner et al., Nature Methods 2:905-909, 2005; and Zhang et al., Nat.Rev. Mol. Biol. 3: 906-918, 2002; Ai et al., Biochemistry 46:5904-5910,2007; Shaner et al., Nat. Biotech 22:1567-1572, 2004; Campbell et al.,Proc. Nat. Acad. Sci. 99:7877-7882, 2002; Heikal et al. Proc. Nat. Acad.Sci. 97:11996-12001, 2000; Baird et al., Proc. Nat. Acad. Sci.97:11984-11989, 2000; Tsien, Ann. Rev. Biochem. 67:509-44, 1998; Heim etal., Curr. Biol. 6:178-182, 1996; Cubitt et al., Trends Biochem Sci.11:448-455, 1995; Heim et al., Proc. Nat. Acad. Sci 91:12501-12504,1994; the relevant text incorporated by reference herein.

Imaging Probes

The imaging system and method can be used with a number of differentimaging probes, for example, (1) probes that become activated aftertarget contact (e.g., binding or interaction) (Weissleder et al., NatureBiotech., 17:375-378, 1999; Bremer et al., Nature Med., 7:743-748, 2001;Campo et al., Photochem. Photobiol. 83:958-965, 2007); (2) wavelengthshifting beacons (Tyagi et al., Nat. Biotechnol., 18:1191-1196, 2000);(3) multicolor (e.g., fluorescent) probes (Tyagi et al., Nat.Biotechnol., 16:49-53, 1998); (4) probes that have high binding affinityto targets, e.g., that remain within a target region while non-specificprobes are cleared from the body (Achilefu et al., Invest. Radiol.,35:479-485, 2000; Becker et al., Nature Biotech. 19:327-331, 2001; Bujaiet al., J. Biomed. Opt. 6:122-133, 2001; Ballou et al. Biotechnol. Prog.13:649-658, 1997; and Neri et al., Nature Biotech. 15:1271-1275, 1997);(5) quantum dot or nanoparticle-based imaging probes, includingmultivalent imaging probes, and fluorescent quantum dots such as amineT2MP EviTags® (Evident Technologies) or Qdot® Nanocrystals(Invitrogen™); (6) non-specific imaging probes e.g., indocyanine green,AngioSense® (VisEn Medical); (7) labeled cells (e.g., such as cellslabeled using exogenous fluorophores such as VivoTag™ 680,nanoparticles, or quantum dots, or by genetically manipulating cells toexpress fluorescent or luminescent proteins such as green or redfluorescent protein; and/or (8) X-ray, MR, ultrasound, PET or SPECTcontrast agents such as gadolinium, metal oxide nanoparticles, X-raycontrast agents including iodine based imaging agents, or radioisotopicform of metals such as copper, gallium, indium, technetium, yttrium, andlutetium including, without limitation, 99m-Tc, 111-In, 64-Cu, 67-Ga,186-Re, 188-Re, 153-Sm, 177-Lu, and 67-Cu. The relevant text of theabove-referenced documents are incorporated by reference herein. Anothergroup of suitable imaging probes are lanthanide metal-ligand probes.Fluorescent lanthanide metals include europium and terbium. Fluorescenceproperties of lanthanides are described in Lackowicz, 1999, Principlesof Fluorescence Spectroscopy, 2^(nd) Ed., Kluwar Academic, New York, therelevant text incorporated by reference herein. In the methods of thisinvention, the imaging probes can be administered systemically orlocally by injecting an imaging probe or by topical or other localadministration routes, such as “spraying”. Furthermore, imaging probesused in the application of this invention can be conjugated to moleculescapable of eliciting photodynamic therapy. These include, but are notlimited to, Photofrin, Lutrin, Antrin, aminolevulinic acid, hypericin,benzoporphyrin derivative, and select porphyrins.

In general, fluorescent quantum dots used in the practice of thisinvention are nanocrystals containing several atoms of a semiconductormaterial (including but not limited to those containing cadmium andselenium, sulfide, or tellurium; zinc sulfide, indium-antimony, leadselenide, gallium arsenide, and silica or ormosil), which have beencoated with zinc sulfide to improve the properties of the fluorescentagents.

In particular, molecular imaging probes are a preferred type of imagingprobe. A molecular imaging probe is a probe that is targeted to abiomarker, molecular structure or biomolecule, such as a cell-surfacereceptor or antigen, an enzyme within a cell, or a specific nucleicacid, e.g., DNA, to which the probe hybridizes. Biomolecules that can betargeted by imaging probes include, for example, antibodies, proteins,glycoproteins, cell receptors, neurotransmitters, integrins, growthfactors, cytokines, lymphokines, lectins, selectins, toxins,carbohydrates, internalizing receptors, enzyme, proteases, viruses,microorganisms, and bacteria.

In certain embodiments, optical imaging probes have excitation andemission wavelengths in the red and near infrared spectrum in the range550-1300 or 400-1300 nm or about 440 and about 1100 nm, between about550 and about 800 nm, between about 600 and about 900 nm. Use of thisportion of the electromagnetic spectrum maximizes tissue penetration andminimizes absorption by physiologically abundant absorbers such ashemoglobin (<650 nm) and water (>1200 nm). Optical imaging probes withexcitation and emission wavelengths in other spectrums, such as thevisible and ultraviolet light spectrum, can also be employed in themethods of the present invention. In particular, fluorophores such ascertain carbocyanine or polymethine fluorescent fluorochromes or dyescan be used to construct optical imaging agents, e.g. U.S. Pat. No.6,747,159 to Caputo et al. (2004); U.S. Pat. No. 6,448,008 to Caputo etal. (2002); U.S. Pat. No. 6,136,612 to Della Ciana et al. (2000); U.S.Pat. No. 4,981,977 to Southwick, et al. (1991); 5,268,486 to Waggoner etal. (1993); U.S. Pat. No. 5,569,587 to Waggoner (1996); 5,569,766 toWaggoner et al. (1996); U.S. Pat. No. 5,486,616 to Waggoner et al.(1996); U.S. Pat. No. 5,627,027 to Waggoner (1997); U.S. Pat. No.5,808,044 to Brush, et al. (1998); U.S. Pat. No. 5,877,310 toReddington, et al. (1999); U.S. Pat. No. 6,002,003 to Shen, et al.(1999); U.S. Pat. No. 6,004,536 to Leung et al. (1999); U.S. Pat. No.6,008,373 to Waggoner, et al. (1999); U.S. Pat. No. 6,043,025 to Minden,et al. (2000); U.S. Pat. No. 6,127,134 to Minden, et al. (2000); U.S.Pat. No. 6,130,094 to Waggoner, et al. (2000); U.S. Pat. No. 6,133,445to Waggoner, et al. (2000); U.S. Pat. No. 7,445,767 to Licha, et al.(2008); U.S. Pat. No. 6,534,041 to Licha et al. (2003); U.S. Pat. No.7,547,721 to Miwa et al. (2009); U.S. Pat. No. 7,488,468 to Miwa et al.(2009); U.S. Pat. No. 7,473,415 to Kawakami et al. (2003); also WO96/17628, EP 0 796 111 B1, EP 1 181 940 B1, EP 0 988 060 B1, WO98/47538, WO 00/16810, EP 1 113 822 B1, WO 01/43781, EP 1 237 583 A1, WO03/074091, EP 1 480 683 B1, WO 06/072580, EP 1 833 513 A1, EP 1 679 082A1WO 97/40104, WO 99/51702, WO 01/21624, and EP 1 065 250 A1; andTetrahedron Letters 41, 9185-88 (2000); all of the above incorporated byreference herein.

Exemplary fluorochromes for optical imaging probes include, for example,the following: Cy5.5, Cy5, Cy7.5 and Cy7 (GE® Healthcare);AlexaFluor660, AlexaFluor680, AlexaFluor790, and AlexaFluor750(Invitrogen); VivoTag™680, VivoTag™-S680, VivoTag™-S750 (VIsEN Medical);Dy677, Dy682, Dy752 and Dy780 (Dyomics®); DyLight® 547, and/or DyLight®647 (Pierce); HiLyte Fluor™ 647, HiLyte Fluor™ 680, and HiLyte Fluor™750 (AnaSpec®); IRDye® 800CW, IRDye® 800RS, and IRDye® 700DX (Li-Cor®);ADS780WS, ADS830WS, and ADS832WS (American Dye Source); XenoLight CF™680, XenoLight CF™750, XenoLight CF™770, and XenoLight DiR (Caliper®Life Sciences); and Kodak® X-SIGHT® 650, Kodak® X-SIGHT 691, Kodak®X-SIGHT 751 (Carestream® Health).

Calibration for Concentration Mapping

The systems and methods described herein allow in vivo quantification offluorescent agents in an animal subject. The systems can accuratelyreconstruct the concentration of fluorescent agents as a function oflocation within the animal subject. Numerical computation of thedistribution of fluorescent agents produces results that are dependenton the photochemical properties of the fluorescent agents as conjugatedwith biologically relevant probes. Specifically, the product of thequantum yield and absorption cross-section, or extinction coefficient,are included as numerical factors in the computational result, therebymasking the actual fluorochrome concentration. A priori estimation ofthese photochemical properties from first principles and application ofsuch estimates to a tomographic reconstruction of in vivo fluorescenceis unreliable and prone to error. Thus, there is a need for a method toaccount for these photochemical properties empirically and in vivo, inorder to yield accurate quantification and allocation of fluorescentagent concentration.

The calibration method enables accurate quantification of FMTtomographic reconstructions of the distribution of fluorescent agent.The method involves the measurement by FMT of a known amount offluorescent agent in solution (for example VivoTag680 or VivoTag750,VisEn Medical, Bedford, Mass.), injected into a phantom. This phantomcan either be a synthetic material designed to match the opticalproperties of animal tissue and containing a cavity designed to hold thefluorescent agent, or it can be a container holding fluorescent agentthat is in turn placed inside an animal cadaver. Phantom material may,for example, consist of an optically clear polyester resin (TAPPlastics, Dublin, Calif.) with a dispersion of Titanium Dioxide (TiO2,Sigma-Aldrich, St. Louis, Mo.) and ink to adjust the optical scatteringand optical absorption properties of the phantom to those of biologicaltissue. Phantoms may be molded, machined or fabricated to any desiredgeometry or aspect ratio. In one embodiment, phantoms are molded todimensions representative of small animal anatomies (such as thicknessesspanning a range of 13-25 mm) and machined with internal hollow cavitiesto accommodate fluorescent agents with dimensions representative ofdisease-related lesions in various animal models (such as tumor sizes inthe range of 50-500 μL). These hollow cavities may be located at depthsrepresentative of various disease manifestations, from close to thesurface (for subcutaneous disease models) to full depth within thephantom. The concentration of fluorescent agent in solution is measuredin vitro, for example using spectrophotometry instrumentation such asthe devices provided by Varian (Palo Alto, Calif.), before dispensing aknown volume of the solution into the phantom. A complete FMT dataset ofthe phantom is then acquired, and the raw data are tomographicallyreconstructed. A region of interest (ROI) analysis is performed on thereconstructed distribution of fluorescent agent. The values in this ROIare then numerically scaled to match the known amount of fluorescentagent that had been dispensed into the phantom. Finally, this scalefactor is applied to future reconstructions to convert the raw result ofthe tomographic reconstruction into a physically meaningfulconcentration of fluorescent agent. Scale factors can be generated toaccount for the photochemical properties of different fluorescentagents, such as ProSense680, OsteoSense750 and others (VisEn Medical,Bedford, Mass.). This calibration process may be repeated several timesper agent to increase the statistical robustness of the calibration anddecrease the impact of operator variability, batch to batch agentvariability, and other sources of error. It is also possible to generatea single, scalar scale factor or a scale factor function mapping to anentire range of concentrations, as appropriate. The scale factor mayalso be a function of depth within the subject being scanned or of otherphysical properties of the subject. These functional scale factors mayalso be combined to produce a scale factor function with multipleparameters. Calibration of phantoms using the virtual index-matchingapproach is depicted in FIG. 9, panel 902.

The following references, and all other references identified herein,are incorporated by reference herein in their entirety: Arridge, S. R.,H. Dehghani, et al. (2000), “The finite element model for thepropagation of light in scattering media: a direct method for domainswith nonscattering regions,” Med Phys 27(1): 252-64; Hielscher, A. H.,R. E. Alcouffe, et al. (1998), “Comparison of finite-differencetransport and diffusion calculations for photon migration in homogeneousand heterogeneous tissues,” Phys. Med. Biol. 43: 1285-1302; Markel, V.A. and J. C. Schotland (2001), “Inverse scattering for the diffusionequation with general boundary conditions,” Phys Rev E 64(3 Pt 2):035601; Markel, V. A. and J. C. Schotland (2004), “Symmetries, inversionformulas, and image reconstruction for optical tomography,” Phys Rev EStat Nonlin Soft Matter Phys 70(5 Pt 2): 056616; Ntziachristos, V., J.Ripoll, et al. (2005), “Looking and listening to light: the evolution ofwhole-body photonic imaging,” Nat Biotechnol 23(3): 313-20;

-   Ripoll, J., M. Nieto-Vesperinas, et al. (2002), “Fast analytical    approximation for arbitrary geometries in diffuse optical    tomography,” Optics Letters 27(7): 527-529; Ripoll, J., V.    Ntziachristos, et al. (2001), “The Kirchhoff Approximation for    diffusive waves,” Phys. Rev. E 64: 051917: 1-8.

EQUIVALENTS

While the invention has been particularly shown and described withreference to specific preferred embodiments, it should be understood bythose skilled in the art that various changes in form and detail may bemade therein without departing from the spirit and scope of theinvention as defined by the appended claims. The relevant teachings ofall the references, patents and patent applications cited herein areincorporated herein by reference in their entirety.

1. A fluorescence molecular tomography imaging system comprising: anexcitation light source; an optical imaging apparatus configured todirect light from the excitation light source into a subject at aplurality of locations; a detector configured to detect at multiplelocations fluorescent light emanating from a region within the subject;and a processor configured to process data corresponding to the detectedfluorescent light emanating from the region of the subject to produce atomographic representation of the region of the subject, wherein theprocessor is configured to execute instructions to: (a) establish aforward model of excitation light propagation from the excitation lightsource to the region of the subject and of fluorescent light propagationfrom the region to the detector using the data corresponding to thedetected fluorescent light, wherein one or more virtual-matchingtransformation(s) is/are applied to the data corresponding to thedetected fluorescent light to account for a refractive indexdiscontinuity at the surface of the subject, and the forward model isestablished as a weight matrix of elements using one or more functionssuch that light propagation is modeled as if the subject is surroundedby an infinite and homogeneous diffusive medium and there is nodiscontinuity in refractive index at the surface of the subject; and (b)invert the weight matrix to obtain the tomographic representation of theregion of the subject.
 2. The system of claim 1, wherein, in the forwardmodel, the excitation light source is represented in real space and thedetected fluorescent light is represented in frequency space, andwherein the tomographic representation of the region of the subject is arepresentation in real space.
 3. The system of claim 1, wherein, in theforward model, virtual detectors are established that conform to animposed geometry different from the arrangement of the actual detectors,and the forward model simulates light propagation from the region of thesubject to the virtual detectors.
 4. The system of claim 3, wherein theimposed geometry is a planar array.
 5. The system of claim 1, whereinthe detector is further configured to detect at multiple locationsexcitation light emanating from the subject, and wherein the processoris configured to execute instructions to establish the forward modelusing the data corresponding to the detected excitation light and thedetected fluorescent light.
 6. The system of claim 5, wherein, in theforward model, one or more virtual-matching transformations is/areapplied to the data corresponding to the detected excitation light. 7.The system of claim 5, wherein, in the forward model, the excitationlight source is represented in real space, the detected excitation lightis represented in frequency space, the detected fluorescent light isrepresented in frequency space, and the tomographic representation ofthe region of the subject is a representation in real space.
 8. Thesystem of claim 1, wherein an experimental measurement of surface fluxdistribution is used in the forward model.
 9. The system of claim 1,wherein the detected fluorescent light is emitted from a probe withinthe region of the subject, and the forward model in (a) modelsexcitation light propagation from the excitation light source to theprobe and emitted fluorescent light propagation from the probe to thedetector.
 10. The system of claim 9, wherein, in the forward model, aBorn approximation is used to express an intensity of the detectedfluorescent light emitted from the probe having spatially-varyingconcentration within the region.
 11. The system of claim 1, wherein theintensity of the detected fluorescent light is normalized using anintensity of spatially-corresponding detected excitation light.
 12. Thesystem of claim 11, wherein the forward model is established as a weightmatrix of normalized elements.
 13. The system of claim 5, wherein theforward model in (a) represents the detected excitation light and thedetected fluorescent light in corresponding virtually-matchedexpressions.
 14. The system of claim 1, wherein the excitation lightsource or the optical imaging apparatus comprises a scanner configuredto direct light into the subject at a plurality of locations, therebydefining a plurality of source locations.
 15. The system of claim 14,wherein the plurality of source locations are non-uniformly spaced. 16.The system of claim 1, wherein the excitation light comprises at leastone member selected from the group consisting of continuous wave light,time-resolved light, and intensity modulated light.
 17. The system ofclaim 1, wherein the forward model in (a) models excitation lightpropagation from the excitation light source to the region of thesubject and fluorescent light propagation from the region to thedetector, where there is free space between the surface of the subjectand the detector.
 18. A method of imaging a distribution of afluorescent probe within a region of a subject, the method comprisingthe steps: (a) administering to the subject a probe comprising anear-infrared fluorophore; (b) directing near-infrared excitation lightinto the subject at multiple locations to transilluminate through orreflect from at least a portion of the region of the subject containingthe fluorescent probe; (c) detecting excitation light transmittedthrough or reflected from the region of the subject; (d) detectingfluorescent light emitted from the probe within the subject; and (e)processing data corresponding to the detected fluorescent light and thedetected excitation light to provide a tomographic representation of theregion of the subject, wherein the processing step comprises: (i)establishing a forward model of excitation light propagation from anexcitation light source to the probe within the subject and of emissionlight propagation from the probe to a detector using the datacorresponding to the detected fluorescent light and the detectedexcitation light, wherein one or more virtual-matching transformation(s)is/are applied to the data corresponding to the detected fluorescentlight and the data corresponding to the detected excitation light toaccount for a refractive index discontinuity at the surface of thesubject; an intensity of the detected fluorescent light is normalizedusing an intensity of spatially-corresponding detected excitation light;and the forward model is established as a weight matrix of normalizedelements using one or more functions such that light propagation ismodeled as if the subject is surrounded by an infinite and homogeneousdiffusive medium and there is no discontinuity in refractive index atthe surface of the subject; and (ii) inverting the weight matrix toobtain the tomographic representation of the region of the subject. 19.The method of claim 18, wherein the tomographic representation comprisesa map of concentration of the probe within the region of the subject.20. The method of claim 18, wherein the tomographic representationindicates an area of disease within the region of the subject.
 21. Themethod of claim 18, wherein the tomographic representation indicates anarea of arthritis, cancer, metastasis, plaque, or a combination of twoor more of the foregoing, within the region of the subject.
 22. Themethod of claim 18, wherein the tomographic representation indicates aboundary of a tumor within the region of the subject.
 23. The method ofclaim 18, wherein the probe is an endogenous probe.
 24. The method ofclaim 18, wherein the probe is administered to the subject.
 25. Themethod of claim 18, wherein the probe comprises a member selected fromthe group consisting of a molecular probe, a fluorescent molecularprobe, an activatable fluorescent probe, an enzyme-activatablefluorescent probe, a targeted fluorescent probe, a near-infraredfluorescent molecular probe, a fluorescent protein, a fluorescentbiomolecule, a non-specific fluorescent probe, quantum dots, areceptor-targeted near-infrared fluorochrome, an antibody- orantibody-like targeted near-infrared fluorochrome, a wavelength-shiftingbeacon, a multi-color fluorescence probe, and a lanthanide metal-ligandprobe.
 26. The method of claim 18, wherein the probe comprises afluorochrome attached to a delivery vehicle comprising any one or moreof a polymer, a dendrimer, a protein, a carbohydrate, a lipid sphere,and a nanoparticle.
 27. The method of claim 18, wherein step (a)comprises administering to the subject a plurality of probes havingoptically distinguishable fluorescent emission wavelengths, step (d)comprises detecting fluorescent light emitted from each of the probes,and step (e) comprises processing data corresponding to the detectedlight to provide one or more tomographic representations.
 28. The methodof claim 18, further comprising determining an effect of the probe onthe region within the object using the tomographic representation. 29.The method of claim 18, wherein at least steps (b), (c), (d), and (e)are repeated to obtain tomographic representations as a function oftime, and wherein the method comprises monitoring kinetics of adistribution or activation of the probe within the region using thetomographic representations.
 30. The method of claim 18, furthercomprising imaging at excitation and emission wavelengths of a naturaltissue chromophore.
 31. The method of claim 18, wherein the tomographicrepresentation comprises a map showing quantity of the probe in threedimensions.
 32. The method of claim 18, wherein the tomographicrepresentation comprises one or more images, and wherein the methodfurther comprises storing the one or more images, displaying the one ormore images, or both storing and displaying the one or more images. 33.The method of claim 18, wherein the tomographic representation comprisesa three-dimensional tomographic image and wherein the method furthercomprises combining the three-dimensional tomographic image withmagnetic resonance, x-ray computed tomography, bioluminescencetomography, spectroscopy, ultrasound, single photon emission tomography,or positron emission tomography imaging data.
 34. The method of claim18, further comprising the step of detecting or monitoring a cellularabnormality or disease using the tomographic representation, wherein thecellular abnormality or disease comprises at least one member selectedfrom the group consisting of inflammation, cancer, cardiovasculardisease, respiratory disease, dermatologic disease, ophthalmic disease,infectious disease, immunologic disease, central nervous system disease,inherited disease, metabolic disease, environmental disease,bone-related disease, neurodegenerative disease, and surgery-relatedcomplication.
 35. An apparatus for reconstructing a tomographicrepresentation of a probe within a region of a subject, the apparatuscomprising: a memory that stores code defining a set of instructions;and a processor that executes the instructions thereby to: (a) establisha forward model of excitation light propagation from an excitation lightsource to the probe within the region of the subject and of emissionlight propagation from the probe to a detector using data correspondingto detected fluorescent light from the probe and using datacorresponding to detected excitation light transmitted through orreflected from the region of the subject, wherein one or morevirtual-matching transformation(s) is/are applied to the datacorresponding to the detected fluorescent light and the datacorresponding to the detected excitation light to account for arefractive index discontinuity at the surface of the subject; anintensity of the detected fluorescent light is normalized using anintensity of spatially-corresponding detected excitation light; and theforward model is established as a weight matrix of normalized elementsusing one or more functions such that light propagation is modeled as ifthe subject is surrounded by an infinite and homogeneous diffusivemedium and there is no discontinuity in refractive index at the surfaceof the subject; and (b) invert the weight matrix to obtain thetomographic representation of the region of the subject.
 36. Theapparatus of claim 35, wherein the processor executes the instructionsto establish the forward model, wherein the excitation light source isrepresented in real space, the detected fluorescent light and thedetected excitation light are represented in frequency space, and thetomographic representation of the region of the subject is arepresentation in real space.
 37. A diffuse optical tomography imagingsystem comprising: one or more illumination sources; an optical imagingapparatus configured to direct light from the at least one illuminationsource into a subject at a plurality of locations; a detector configuredto detect at multiple locations light emanating from the subject toobtain a first and a second measurement, wherein the first measurementis a reference measurement and the second measurement corresponds toabsorption of at least a portion of the illuminating light as it passesthrough a light-absorbing region within the subject, and wherein thereference measurement does not reflect all of said absorption; and aprocessor configured to process data corresponding to the first andsecond measurements of detected light emanating from the subject,wherein the processor is configured to execute instructions to: (a)establish a forward model of light propagation from at least one of theone or more illumination sources to the light-absorbing region withinthe subject and of light propagation from the region to the detectorusing the data corresponding to the first and second measurements,wherein one or more virtual-matching transformation(s) is/are applied tothe data corresponding to the detected light to account for a refractiveindex discontinuity at the surface of the subject, and the forward modelis established as a weight matrix of elements using one or morefunctions such that light propagation is modeled as if the subject issurrounded by an infinite and homogeneous diffusive medium and there isno discontinuity in refractive index at the surface of the subject; and(b) invert the weight matrix to obtain a tomographic representation ofthe region of the subject.
 38. The system of claim 37, comprising atleast two illumination sources having different wavelengths.
 39. Thesystem of claim 38, wherein the different wavelengths comprise awavelength below an isosbestic point of an oxy-hemoglobin (HbO) and adeoxy-hemoglobin (Hb), and a wavelength above the isosbestic point. 40.The system of claim 1, wherein the tomographic representation of theregion of the subject displays a quantitative concentration of afluorophore within the subject in three dimensions.
 41. The system ofclaim 11, wherein the detected excitation light is detected afterpassing through at least a portion of the subject.
 42. The system ofclaim 41, wherein the subject is transilluminated with excitation light.43. The system of claim 1, wherein, in the forward model, datacorresponding to the detected fluorescent light is processed to detectand compensate for the effects of optical heterogeneity in the medium.44. The method of claim 18, wherein step (e) comprises processing datacorresponding to the detected fluorescent light to detect and compensatefor the effects of optical heterogeneity in the medium.